Aytu BioPharma (AYTU) 10-K 26 Sep 24 2024 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2024	Sep. 16, 2024	Dec. 29, 2023
Document Information [Line Items]
Entity Central Index Key	0001385818
Entity Registrant Name	AYTU BIOPHARMA, INC
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-38247
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-0883144
Entity Address, Address Line One	7900 East Union Avenue, Suite 920
Entity Address, City or Town	Denver
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80237
City Area Code	720
Local Phone Number	437-6580
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	AYTU
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 10,712,951
Entity Common Stock, Shares Outstanding		6,148,993
Auditor Firm ID	248
Auditor Name	GRANT THORNTON LLP
Auditor Location	Denver, Colorado

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Current assets:
Cash and cash equivalents	$ 20,006	$ 22,985
Accounts receivable, net	23,617	28,937
Inventories	12,633	11,995
Prepaid expenses and other current assets	5,635	7,162
Total current assets	61,891	71,079
Non-current assets:
Property, Plant and Equipment, Net	693	1,815
Operating lease right-of-use assets	829	2,054
Intangible assets, net	52,453	58,970
Other non-current assets	2,229	2,545
Total non-current assets	56,204	65,384
Total assets	118,095	136,463
Liabilities, Current [Abstract]
Accounts payable	10,440	13,478
Accrued liabilities	38,574	46,799
Revolving credit facility	2,395	1,563
Long-Term Debt, Current Maturities	1,857	85
Other Liabilities, Current	8,962	7,090
Total current liabilities	62,228	69,015
Liabilities, Noncurrent [Abstract]
Debt, net of current portion	10,877	14,713
Derivative warrant liabilities	12,745	6,403
Other Liabilities, Noncurrent	4,529	6,975
Total non-current liabilities	28,151	28,091
Commitments and contingencies (note 18)
Stockholders’ equity
Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, par value $.0001; 200,000,000 shares authorized; 5,972,638 and 5,517,174 shares issued and outstanding, respectively	1	1
Additional paid-in capital	347,688	343,485
Accumulated deficit	(319,973)	(304,129)
Total stockholders’ equity	27,716	39,357
Total liabilities and stockholders’ equity	$ 118,095	$ 136,463

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2024	Jun. 30, 2023
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorizzed (in shares)	50,000,000	50,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	200,000,000	200,000,000
Common stock, issued (in shares)	5,972,638	5,517,174
Common stock, outstanding (in shares)	5,972,638	5,517,174

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Net revenue	$ 81,002	$ 107,399
Cost of sales	26,416	40,767
Gross profit	54,586	66,632
Operating expenses:
Selling and marketing	26,958	41,448
General and administrative	22,514	28,630
Research and development	2,791	4,095
Amortization of intangible assets	5,212	4,788
Restructuring costs	2,365	0
Impairment expense	0	5,705
Gain from contingent consideration	0	(969)
Total operating expenses	59,840	83,697
Loss from operations	(5,254)	(17,065)
Other income, net	568	184
Interest expense	(4,792)	(4,963)
Derivative, Gain (Loss) on Derivative, Net	(4,004)	4,793
Loss before income tax	(14,076)	(17,051)
Income tax expense	(1,768)	0
Net loss	$ (15,844)	$ (17,051)
Basic and diluted weighted-average common shares outstanding (in shares)	5,537,957	3,339,906
Basic and diluted net loss per share (in dollars per share)	$ (2.86)	$ (5.11)
Avenue Capital Loan [Member]
Operating expenses:
Loss on extinguishment of debt	$ (594)	$ 0

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Jun. 30, 2022	1,928,941
Balance at Jun. 30, 2022	$ 0	$ 331,386	$ (287,078)	$ 44,308
Stock-based compensation expense (in shares)	(18,180)
Stock-based compensation expense	$ 0	6,046	0	6,046
Issuance of common stock, net of $1,004 issuance cost (in shares)	3,606,413
Issuance of common stock, net of $1,004 issuance cost	$ 1	6,053	0	6,054
Net loss	$ 0		(17,051)	(17,051)
Balance (in shares) at Jun. 30, 2023	5,517,174
Balance at Jun. 30, 2023	$ 1	343,485	(304,129)	39,357
Stock-based compensation expense (in shares)	14,250
Stock-based compensation expense	$ 0	2,913	0	2,913
Net loss	$ 0		(15,844)	(15,844)
Issuance of common stock from exercise of warrants (in shares)	441,214
Issuance of common stock from exercise of warrants	$ 0	1,290	0	1,290
Balance (in shares) at Jun. 30, 2024	5,972,638
Balance at Jun. 30, 2024	$ 1	$ 347,688	$ (319,973)	$ 27,716

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parentheticals) $ in Thousands	12 Months Ended
	Jun. 30, 2023 USD ($)
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 1,004

Unaudited Consolidated Statemen

Unaudited Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (15,844)	$ (17,051)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation, amortization and accretion	8,272	8,815
Stock-based compensation expense	2,913	6,046
Derivative warrant liabilities loss (gain)	4,004	(4,793)
Amortization of debt discount and issuance costs	597	559
Inventory write-down	2,270	2,351
Asset Impairment Charges	0	5,705
Gain from contingent consideration	0	(969)
Non-cash loss on extinguishment of debt	400	0
Other non-cash adjustments	660	7
Changes in operating assets and liabilities:
Accounts receivable, net	5,320	(7,153)
Inventories	(2,908)	(3,609)
Prepaid expenses and other current assets	1,527	846
Accounts payable	(2,879)	2,384
Accrued liabilities	(9,567)	3,605
Other operating assets and liabilities, net	3,847	(1,872)
Net cash used in operating activities	(1,388)	(5,129)
Cash flows from investing activities:
Other investing activities	(329)	(117)
Net cash used in investing activities	(329)	(117)
Cash flows from financing activities:
Net proceeds from issuance of common stock and warrants	3,467	15,575
Payment made to fixed payment arrangement	(2,566)	(4,266)
Net proceeds (payments) made on revolving credit facility	832	(2,250)
Payments made to borrowings	(15,722)	(96)
Proceeds from borrowings	13,000	0
Payment for debt issuance costs	(273)	(92)
Net cash (used in) provided by financing activities	(1,262)	8,871
Net change in cash and cash equivalents	(2,979)	3,625
Cash and cash equivalents at beginning of period	22,985	19,360
Cash and cash equivalents at end of period	20,006	22,985
Supplemental disclosure of cash flows information:
Cash paid for interest	4,039	3,812
Cash paid for income taxes	1,608	0
Non-cash investing and financing activities:
Other non-cash investing and financing activities	$ 787	$ 147

Note 1 - Nature of Business and

Note 1 - Nature of Business and Financial Condition	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 Aytu BioPharma, Inc. (“Aytu,” the “Company,” “we,” “us,” or “our”), is a pharmaceutical company focused on commercializing novel therapeutics. The Company was originally incorporated as Rosewind Corporation on August 9, 2002, June 8, 2015. March 2021 ( The Company’s strategy is to become a leading pharmaceutical company that improves the lives of patients. The Company uses a focused approach of in-licensing, acquiring, developing, and commercializing novel prescription therapeutics in order to continue building its portfolio of revenue-generating products and leveraging its commercial team’s expertise to build leading brands within large therapeutic markets. The Company’s primary focus is on commercializing innovative prescription products that address conditions frequently developed or diagnosed in childhood, including attention deficit hyperactivity disorder (“ADHD”). The Company operates through two third The Rx Segment primarily consists of two first second first two The Consumer Health Segment consisted of multiple consumer health products competing in large healthcare categories including allergy, hair regrowth, diabetes support, digestive health, sexual and urological health and general wellness, which was commercialized through direct mail and e-commerce marketing channels. The Company began to wind down the Consumer Health Segment in fiscal 2024. first 2025, During the fourth 2024, January 2025, June 2028. June 2028 June 30, 2024 ( Note 10 Note 11 2024 June 30, 2024, 10 June 30, 2024 ( 10 10 not The Company’s consolidated financial Statements and notes thereto have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2 Principals of Consolidation The Company’s consolidated financial statements and notes thereto include the accounts of: Aytu Therapeutics, LLC, Innovus Pharmaceuticals, Inc. and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Basis of Presentation The Company’s consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) Going Concern Determination In connection with the preparation for each annual and interim financial reporting period, management evaluates whether there are events that, in the aggregate, raise substantial doubt about the Company’s ability to continue as a going concern within one one Note 1 Use of Estimates The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results may not Prior Period Reclassification . Certain prior year amounts in the Company’s consolidated financial statements and the notes thereto have been reclassified to conform to the current year presentation. These reclassifications did not June 30, 2024, 2023, June 30, 2024 June 30, 2023 Previously Reported Prepaid Expenses Information During the year ended June 30, 2024, June 30, 2023, June 30, 2023. No. 99, not 10 Cash and Cash Equivalents The Company’s primary objectives for investment of available cash are the preservation of capital and the maintenance of liquidity. The Company invests its available cash balances in bank deposits and money market funds. The cash balances in bank deposits are subject to the Federal Deposit Insurance Corporation (“FDIC”) insurance limits, and cash balances in the money market funds are not three Accounts Receivable, Net Accounts receivable represent amounts due from customers less allowances for credit losses, discounts and pricing chargebacks. An allowance for credit losses, when needed, is based on the best estimate of the amount of probable credit losses in existing accounts receivable, which is determined from the Company’s historical write-off experience and expected future default probabilities based on ongoing evaluations of Company’s customers’ financial condition; payment history; collections experience on other accounts; and economic factors or events expected to affect future collections. An allowance for credit losses, when needed, consists of an amount identified for specific customers and an amount based on overall estimated exposure. Accounts receivable are customer obligations due under normal trade terms. Recovery of bad debt amounts which were previously written off are recorded as a reduction of bad debt expense in the period the payment is collected. If the Company’s actual collection experience changes, revisions to the Company’s allowance for credit losses may zero June 30, 2024, 2023. June 30, 2024, 2023, June 30, 2024, 2023. The table below presents the opening and closing balances of accounts receivable, gross from customers. ​ Accounts Receivable, Gross ​ (in thousands) Balance, June 30, 2022 $ 24,219 Increase in accounts receivable, gross 7,708 Balance, June 30, 2023 31,927 Decrease in accounts receivable, gross (6,488 ) Balance, June 30, 2024 $ 25,439 The table below details the change in allowance for discounts and allowance for chargebacks for the periods presented. ​ Allowance for Discounts Allowance for Chargebacks Total Allowance ​ (in thousands) Balances, June 30, 2022 $ 1,301 $ 1,206 $ 2,507 Reduction of net revenue 9,074 4,554 13,628 Payments (8,597 ) (4,548 ) (13,145 ) Balances, June 30, 2023 1,778 1,212 2,990 Reduction of net revenue 4,886 3,812 8,698 Payments (6,024 ) (3,842 ) (9,866 ) Balances, June 30, 2024 $ 640 $ 1,182 $ 1,822 Inventories Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first first The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are no Property and Equipment Property and equipment are recorded at cost less accumulated depreciation. Furniture and equipment are depreciated on a straight-line basis over their estimated useful lives which are generally two seven Leases At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease. Lease classification, recognition and measurement are determined at the lease commencement date. Lease liabilities and right-of-use (“ROU”) assets are recorded based on the present value of lease payments over the expected lease term, including options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. In determining the present value of the lease payments, the Company uses the implicit interest rate when readily determinable and uses the Company’s incremental borrowing rate when the implicit rate is not Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of sales and operating expenses in the Company’s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of sales and interest expense, respectively, in the Company’s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of 12 Operating leases are included in other liabilities in the Company’s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of debt and debt, net of current portion in the Company’s consolidated balance sheets. Fair Value of Financial Instruments Acquisitions In an acquisition of a business or a group of assets, the Company uses the acquisition method of accounting which identifies, recognizes, and measures the identifiable assets acquired, liabilities assumed and any non-controlling interest at their acquisition date fair values. Any excess of the purchase consideration over the fair values of the net identifiable assets acquired is recorded as goodwill. If the Company determines the assets acquired do not not Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, 480” 815, 815” 480, 480, 815, Revenue Recognition The Company generates revenue from product sales through its Rx Segment and its Consumer Health Segment. The Company evaluates its contracts with customers to determine revenue recognition using the following five 1 2 3 4 5 not Rx Segment Net product sales for the Rx Segment (which includes the ADHD Portfolio and the Pediatric Portfolio) consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx Segment net revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally “free-on-board” destination when shipped domestically within the United States and “free-on-board” shipping point when shipped internationally consistent with the contractual terms. The Company expenses the incremental costs to obtain a contract as incurred, since they are satisfied within one Rx Segment net revenue is recognized net of consideration paid to the Company’s customers and other adjustments to the transaction price (known as “Gross to Net” adjustments). Significant judgement is required in estimating Gross to Net adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel. The Gross to Net adjustments include: ● Savings offers. ● Prompt payment discounts. ● Wholesale distribution fees. ● Rebates. third ● Wholesaler chargebacks. ● Returns. six twelve Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which may may not not Consumer Health Segment The Consumer Health Segment, which was divested of in the first 2025, one Concentration of Credit Risk . Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents and accounts receivable. The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is not The Company is also subject to credit risk from accounts receivable related to product sales. The Company’s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company’s products to retailers. The loss of one not thirty sixty The following table presents customers that contributed more than 10% : ​ Percentage of Gross Revenue Percentage of Accounts Receivable ​ June 30, June 30, ​ 2024 2023 2024 2023 Customer A 33 % 43 % 40 % 50 % Customer B 20 % 18 % 29 % 19 % Customer C 17 % 17 % 11 % 14 % Costs of Sales Costs of sales consists primarily of manufactured product cost, products acquired from third may third Stock-Based Compensation Expense The Company accounts for stock-based payment compensation expense using a fair value based model. Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company’s common stock and recognized ratably over the requisite service period. Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the “simplified method,” which is the midpoint between the vesting date and the end of the contractual term and is utilized by the Company as it does not not Employee Benefits Plan The Company has a 401 401 401 first 401 June 30, 2024, 2023. Research and Development Research and development costs are expensed as incurred and include salaries and benefits; facilities costs; overhead costs; raw materials; laboratory and clinical supplies; clinical trial costs; contract services; milestone payments and fees paid to regulatory authorities for review and approval of the Company’s product candidates; and other related costs. Intangible Assets The Company records acquired intangible assets based on fair value on the date of acquisition. Finite-lived intangible assets are recorded at cost and amortized on a straight-line basis over the estimated lives of the assets. Indefinite-lived intangible assets are not Impairment of Long-lived Assets The Company assesses impairment of asset groups, including intangible assets, when events or changes in circumstances indicate that their carrying amount may not not not Contingent Consideration The consideration for the Company's acquired businesses and licenses often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income, which resulted in a gain from contingent consideration of zero June 30, 2024, 2023, not June 30, 2024, 2023. Advertising and Direct Marketing Costs Advertising and direct marketing costs consist of the direct marketing activities related to the Consumer Health Segment. The Company expenses all advertising costs as incurred. The Company incurred $4.9 million and $17.2 million of advertising costs for the years ended June 30, 2024, 2023 Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not not The Company recognizes the effect of income tax positions only if those positions are more likely than not Debt Discount and Issuance Costs Debt issuance costs reflect fees paid to lenders and third Segment Information The Company’s operating segments engage in business activities from which it may two Paragraph IV Litigation Costs Legal costs incurred by the Company in the enforcement of the Company’s intellectual property rights are charged to expense. Business Combinations The Company recognizes the identifiable tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The excess of purchase price over the aggregate fair values is recorded as goodwill. The Company calculates the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed to allocate the purchase price at the acquisition date. Employee Retention Credit On March 27, 2020, 19 70% December 31, 2020, September 30, 2021. 19 As there is no 20, 20” 20, first 2024. 20, 1986, first 2024. Net Income (Loss) Per Share Basic net income (loss) per share is calculated by dividing the net income (loss) available to the common stockholders by the weighted average number of common shares outstanding during that period. Diluted net income (loss) per share reflects the potential of securities that could share in the net income (loss) of the Company. For the years ended June 30, 2024, 2023 not The following table sets forth securities excluded from the calculation of diluted earnings per share. ​ ​ ​ June 30, ​ ​ 2024 2023 Warrants to purchase common stock - liability classified (Note 16) 6,057,766 6,498,980 Warrants to purchase common stock - equity classified (Note 16) 18,114 39,072 Employee stock options (Note 15) 146,539 52,762 Employee unvested restricted stock (Note 15) 25,360 40,996 Employee unvested restricted stock units (Note 15) 1,775 4,963 Total ​ 6,249,554 6,636,773 Recently Adopted Accounting Pronouncements Financial Instruments - Credit Losses In June 2016, No. 2016 13, Financial Instruments—Credit Losses 2016 13” 2016 13 December 15, 2019. October 2019, December 15, 2022. 2022 02 2016 13. 2016 13 2019 05 July 1, 2023. 2016 13, 2019 05, 2022 02 not Recent Accounting Pronouncements Not Debt Debt with Conversion and Other Options In August 2020, No. 2020 06, Debt—Debt with Conversion and Other Options (Subtopic 470 20 815 40 no December 15, 2023, July 1, 2024, not Segment Reporting In November 2023, No. 2023 07, Segment Reporting (Topic 280 2023 07” 2023 07 2023 07 December 15, 2023, December 15, 2024. Other than the application of IAS 20 no no not June 30, 2024 10

Note 3 - Revenue

Note 3 - Revenue	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 3 The Company disaggregates its revenue into two first 2025. ten Revenues by Segment Net revenue disaggregated by segment for the years ended June 30, 2024, 2023 ​ ​ Year Ended ​ June 30, ​ 2024 2023 ​ (in thousands) Rx Segment net revenue $ 65,183 $ 73,799 Consumer Health Segment net revenue 15,819 33,600 Total net revenue $ 81,002 $ 107,399 ​ Revenues by Product Portfolio Net revenue disaggregated by significant product portfolios in the Rx Segment for the years ended June 30, 2024, 2023 ​ Year Ended ​ June 30, ​ 2024 2023 (in thousands) ADHD Portfolio net revenue $ 57,784 $ 46,855 Pediatric Portfolio net revenue 7,280 25,377 Other 119 1,567 Total Rx Segment net revenue $ 65,183 $ 73,799 ​ Other includes discontinued and deprioritized products in the Rx Segment. The Consumer Health Segment was comprised of one Revenues by Geographic Location Net revenue disaggregated by geographic location as determined by the billing address of the Company’s customers for the years ended June 30, 2024, 2023 ​ Year Ended ​ June 30, ​ 2024 2023 ​ (in thousands) United States net revenue $ 80,911 $ 106,918 International net revenue 91 481 Total net revenue $ 81,002 $ 107,399

Note 4 - Inventories

Note 4 - Inventories	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 4 Inventories consist of the following: ​ June 30, ​ 2024 2023 ​ (in thousands) Raw materials $ 266 $ 1,301 Work in process 5,725 2,956 Finished goods 6,642 7,738 Inventories $ 12,633 $ 11,995 ​ The Company incurred inventory write-downs of $2.3 million for the year ended June 30, 2024, June 30, 2023,

Note 5 - Property and Equipment

Note 5 - Property and Equipment	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 5 Property and equipment, net consist of the following: ​ June 30, ​ 2024 2023 ​ (in thousands) Manufacturing equipment $ 1,117 $ 2,433 Office equipment, furniture and other 945 1,125 Lab equipment 721 832 Leasehold improvements 35 999 Assets under construction — 107 Property and equipment, gross 2,818 5,496 Less accumulated depreciation and amortization (2,125 ) (3,681 ) Property and equipment, net $ 693 $ 1,815 ​ Depreciation expense was $0.9 million and $1.3 million during the years ended June 30, 2024, 2023 June 30, 2024, not June 30, 2023

Note 6 - Leases

Note 6 - Leases	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Leases Disclosure [Text Block]	Note 6 The Company’s operating leases are for its offices, manufacturing facilities and equipment, and its finance leases were for equipment. These leases have original lease periods expiring between 2022 2030. may not June 30, 2024. In connection with the Neos Acquisition, Aytu assumed an operating lease ROU asset and lease liability of $3.5 million, which represented the present value of the remaining lease payments as of the acquisition date, for the office space and manufacturing facilities at Grand Prairie, Texas. As the lease agreement does not During the fourth 2024, December 31, 2026, December 31, 2024, In June 2024, July 2024. July 31, 2030, one five July 2035. not July 2024. In May 2023, September 2023 ( five not Note 18 The components of lease expenses are as follows: ​ Year Ended ​ ​ June 30, ​ ​ 2024 2023 Statement of Operations Classification ​ (in thousands) ​ Lease cost: ​ ​ ​ Operating lease cost $ 2,247 $ 1,402 Operating expenses Short-term lease cost 94 97 Operating expenses Finance lease cost: ​ ​ ​ Amortization of leased assets 53 66 Cost of sales Interest on lease liabilities 3 9 Interest expense Total lease cost $ 2,397 $ 1,574 ​ Supplemental balance sheet information related to leases is as follows: ​ June 30, ​ 2024 2023 Balance Sheet Classification ​ (in thousands) ​ Assets: ​ ​ ​ Operating lease assets $ 829 $ 2,054 Operating lease right-of-use assets Finance lease assets — 159 Property and equipment, net Total lease assets $ 829 $ 2,213 ​ Liabilities: ​ ​ ​ Current: ​ ​ ​ Operating leases $ 712 $ 1,258 Other current liabilities Finance leases — 85 Current portion of debt Non-current: ​ ​ ​ Operating leases 577 832 Other liabilities Total lease liabilities $ 1,289 $ 2,175 ​ The remaining weighted-average lease term and discount rate used are as follows: ​ June 30, ​ 2024 2023 Weighted-average remaining lease term (years): ​ ​ Operating lease assets 2.7 1.7 Finance lease assets — 0.9 Weighted-average discount rate: ​ ​ Operating lease assets 10.0 % 7.8 % Finance lease assets — % 6.5 % Supplemental cash flow information related to leases is as follows: ​ Year Ended ​ June 30, ​ 2024 2023 ​ (in thousands) Cash flow classification of lease payments: ​ ​ Operating cash flows from operating leases $ 1,812 $ 1,436 Operating cash flows from finance leases $ 3 $ 9 Financing cash flows from finance leases $ 85 $ 96 As of June 30, 2024 not June 30, 2024 ​ Operating ​ (in thousands) 2025 $ 970 2026 399 2027 377 2028 386 2029 359 Thereafter 249 Total lease payments 2,740 Less: imputed interest (555 ) Lease liabilities $ 2,185

Note 7 - Intangible Assets

Note 7 - Intangible Assets - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Asset Impairment Charges	$ 0	$ 5,705
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	Note 7 A summary of the Company’s intangible assets as of June 30, 2024 June 30, 2023 ​ June 30, 2024 ​ Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted-Average Remaining Life ​ (in thousands) (in years) Acquired product technology rights $ 41,268 $ (13,184 ) $ 28,084 10.5 Acquired technology rights 30,200 (5,831 ) 24,369 13.8 Total definite-lived intangible assets $ 71,468 $ (19,015 ) $ 52,453 12.0 ​ June 30, 2023 ​ Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted-Average Remaining Life ​ (in thousands) (in years) Acquired product technology rights $ 42,176 $ (10,881 ) $ 31,295 11.5 Acquired technology rights 30,200 (4,054 ) 26,146 14.8 Acquired product distribution rights 6,207 (4,678 ) 1,529 1.0 Total definite-lived intangible assets $ 78,583 $ (19,613 ) $ 58,970 12.7 Gross carrying amounts are net of any impairment charges from prior periods. An intangible asset with zero not June 30, 2024, 2023 The following table summarizes the estimated future amortization expense of intangible assets to be recognized over the next five ​ June 30, ​ (in thousands) 2025 $ 4,989 2026 4,989 2027 4,989 2028 4,989 2029 4,989 Thereafter 27,508 Total future amortization expense $ 52,453 ​ Acquired Product Technology Rights The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisition of the Pediatric Portfolio in November 2019 March 2021. Karbinal The Company acquired and assumed all rights and obligations pursuant to the supply and distribution agreement, as amended, with Tris Pharma, Inc. (“Tris”) for the exclusive rights to commercialize Karbinal in the United States (the “Tris Karbinal Agreement”). The Tris Karbinal Agreement’s initial term terminates in August 2033, Poly-Vi-Flor and Tri-Vi-Flor The Company acquired and assumed all rights and obligations pursuant to a supply and license agreement and various assignment and release agreements, including a previously agreed to settlement and license agreements (the “Poly-Tri Agreements”) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States. ADHD Portfolio As part of the Neos Acquisition, the Company acquired developed product technology for the production and sale of Adzenys and Cotempla. The formulations for the ADHD products are protected by patented technology. The estimated economic life of these proprietary technologies is 16 years. Acquired Technology Right TRRP Proprietary Technology As part of the Neos Acquisition, the Company acquired time release resin particle (“TRRP”) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlines each of the ADHD Portfolio core products and can potentially be used in future product development initiatives as well. Acquired Product Distribution Rights In connection with the acquisition of Innovus Pharmaceuticals, Inc. (“Innovus”) in February 2020 ( 35 300 June 30, 2023, impaired June 30, 2024, Acquired In-Process R&D IPR&D NT0502 As part of the Neos Acquisition, the Company acquired in-process research and development associated with NT0502, June 30, 2023, NT0502. NT0502, second 2023.

Note 8 - Accrued Liabilities

Note 8 - Accrued Liabilities	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Accrued Liabilities [Text Block]	Note 8 Accrued liabilities consist of the following: ​ June 30, ​ 2024 2023 ​ (in thousands) Accrued savings offers $ 11,054 $ 15,739 Accrued program liabilities 9,964 11,012 Accrued customer and product related fees 5,395 6,579 Accrued compensation 4,935 5,675 Return reserve 4,835 5,777 Other accrued liabilities 2,391 2,017 Total accrued liabilities $ 38,574 $ 46,799 Accrued savings offers represent programs for the Company’s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Accrued program liabilities include government and commercial rebates. Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. Accrued employee compensation includes sales commissions, paid time off earned, accrued payroll and accrued bonus. The return reserve represents the Company’s accrual for estimated product returns. Other accrued liabilities consist of various other accruals, none five The following table details the change in return reserve for the periods presented: ​ Return Reserve ​ (in thousands) Balance, June 30, 2022 $ 5,770 Reduction of net revenue 8,353 Payments (8,346 ) Balance, June 30, 2023 5,777 Reduction of net revenue 6,128 Payments (7,070 ) Balance, June 30, 2024 $ 4,835

Note 9 - Other Liabilities

Note 9 - Other Liabilities	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	Note 9 Other liabilities consist of the following: ​ June 30, ​ 2024 2023 ​ (in thousands) Fixed payment arrangements $ 8,337 $ 10,420 Employee retention credit 3,759 — Operating lease liabilities 1,289 2,090 Other 106 1,555 Total other liabilities 13,491 14,065 Less: current portion of other liabilities (8,962 ) (7,090 ) Total other liabilities, non-current $ 4,529 $ 6,975 ​ Fixed payment arrangements Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in 2019, In May 2022, November 2, 2018, June 30, 2024, July 2024. The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was 20 years. The Company pays Tris a royalty equal to 23.5% of net revenue from the product. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 July 31, 2025. 2025. August first June 30, 2024, Employee Retention Credit The $3.8 million ERC accrual in other non-current liabilities as of June 30, 2024, first 2024. Note 2 Operating Lease Liabilities The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment. Please refer to Note 6 Other Other consists of taxes payable, deferred cost related to the Company’s technology transfer, and various other accruals, none five

Note 10 - Revolving Credit Faci

Note 10 - Revolving Credit Facility	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Short-Term Debt [Text Block]	Note 10 On June 12, 2024, No. 5 No. 5” October 2, 2019, No. 1, March 19, 2021, No. 2, January 26, 2022, No. 3, June 1, 2022, No. 4 March 24, 2023, No. 5 No. 5, two Note 11 June 12, 2028, June 30, 2024. In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 2.0% of the Eclipse Revolving Loan commitment if such event occurs on or before June 12, 2025, ( June 12, 2025, June 12, 2026, June 12, 2026, June 12, 2028. may Note 11 may The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company’s obligations under the Eclipse Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of June 30, 2024 The Company allocated debt issuance costs of $0.1 million related to the Eclipse Revolving Loan, bringing to the total debt issuance costs related to the Eclipse Revolving Loan to $0.2 million, which will be amortized straight-line over the term of the loan. June 30, 2024, 2023 June 30, 2024, 2023 June 30, 2024

Note 11 - Long-term Debt

Note 11 - Long-term Debt	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Long-Term Debt [Text Block]	Note 11 Avenue Capital Loan On January 26, 2022 ( January 26, 2025. Pursuant to the Avenue Capital Agreement, the Company was required to make interest only payments for the first 18 six June 15, 2023, 1” six December 31, 2023, ( 1 12 On January 26, 2022 ( June 30, 2022, January 31, 2027. not On March 7, 2022, Note 15 July 7, 2022, March 7, 2022, On October 25, 2022, January 2022, January 2024. August 2022 On June 13, 2023, Note 16 January 26, 2025. In addition to the debt discount discussed above, the Company also incurred $0.4 million loan origination, legal and other fees. The debt discount and issuance costs were being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 16.6%. Total interest expense on the Avenue Capital loan including debt discount amortization, were $3.4 million and $2.7 million for the years ended June 30, 2024, 2023 . On June 12, 2024, fourth 2024. Eclipse Term Loan On June 12, 2024, No. 5, Note 10 four June 12, 2028, seven four June 12, 2028, June 30, 2024. In the event that, for any reason, all or any portion of the Eclipse Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 3.0% of the Eclipse Term Loan if such event occurs on or before June 12, 2025, ( June 12, 2025, June 12, 2026, ( June 12, 2026, June 12, 2027, June 12, 2026, June 12, 2028. may Note 10 may The Eclipse Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make certain asset sales without the prior written consent of the Eclipse Lender. A failure to comply with these covenants could permit the Eclipse Lender to declare the Company’s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of June 30, 2024 The Company recorded total debt discount and allocated debt issuance costs of $0.3 million related to the Eclipse Term Loan, which will be amortized over the term of the loan. The Company incurred interest expense on the Eclipse Term Loan, including debt discount and issuance costs amortization, of $0.1 million for the year ended June 30, 2024. Long-term debt consists of the following: ​ June 30, ​ 2024 2023 ​ (in thousands) Term loan principal amount $ 13,000 $ 15,000 Unamortized debt discount and issuance costs (266 ) (925 ) Final payment fee — 638 Financing leases — 85 Total debt 12,734 14,798 Less: current portion of debt (1,857 ) (85 ) Total debt, net of current portion $ 10,877 $ 14,713 ​ Future principal payments of long-term debt are as follows: ​ June 30, ​ (in thousands) 2025 $ 1,857 2026 1,857 2027 1,857 2028 7,429 Total future term loan principal payments 13,000 Less: unamortized debt discount and issuance costs (266 ) Less: current portion of debt (1,857 ) Total debt, net of current portion $ 10,877

Note 12 - Fair Value Measuremen

Note 12 - Fair Value Measurements - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Asset Impairment Charges	$ 0	$ 5,705
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 12 The Company determines the fair value of financial and non-financial assets using the fair value hierarchy, which establishes three may Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; Level 2: Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities, contingent consideration liabilities, fixed payment arrangements, and current and non-current debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Current and non-current debt are reported at their amortized costs on the Company’s consolidated balance sheets. The remaining financial instruments are reported on the Company’s consolidated balance sheets at amounts that approximate current fair values. The Company’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no 1, 2 3 Recurring Fair Value Measurement The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2024, 2023 ​ ​ Fair Value at Fair Value Measurements at June 30, 2024 ​ June 30, 2024 (Level 1) (Level 2) (Level 3) ​ (in thousands) Liabilities: ​ ​ ​ ​ Derivative warrant liabilities $ 12,745 $ — $ — $ 12,745 Total $ 12,745 $ — $ — $ 12,745 ​ ​ Fair Value at Fair Value Measurements at June 30, 2023 ​ June 30, 2023 (Level 1) (Level 2) (Level 3) ​ (in thousands) Liabilities: ​ ​ ​ ​ Derivative warrant liabilities $ 6,403 $ — $ — $ 6,403 Total $ 6,403 $ — $ — $ 6,403 ​ Cash and cash equivalents in the consolidated balance sheets include bank deposits and money market funds and reflect their fair value at Level 1 Non-Recurring Fair Value Measurement The Company’s financial assets and liabilities that were accounted for at fair value on a non-recurring basis during the years ended June 30, 2024, 2023 Fixed payment arrangements are recognized at their amortized cost basis using market appropriate discount rates and are accreted up to their notional face value over time. Significant assumptions used in valuing the fixed payment arrangements were discount rates from 10.0% to 15.4% and are classified as Level 3 May 2022, Note 9 ​ Based on the Company’s impairment analyses for fiscal 2024 2023 not June 30, 2024 impairment charge June 30, 2023 3 may Note 7 Note 2 Summary of Level 3 The following table sets forth a summary of changes to those fair value measures using Level 3 June 30, 2024 ​ Derivative Warrant ​ Liabilities ​ (in thousands) Balance as of June 30, 2022 $ 1,796 Issued 10,998 Settlements — Included in earnings (6,391 ) Balance as of June 30, 2023 6,403 Issued (1) 5,148 Settlements (1) (2,810 ) Included in earnings 4,004 Balance as of June 30, 2024 $ 12,745 ( 1 Primarily relates to warrants to purchase 2,173,912 common shares issued with the Company’s June 2023 June 2024. Note 14 Note 16 Level 3 Significant assumptions as of June 30, 2024, ​ June 2023 Warrants Warrants ​ Tranche A Other (1) Monte Carlo & Black-Scholes Black-Scholes Aytu closing stock price $ 2.92 $ 2.92 Equivalent term (years) 3.9 2.6 - 3.2 Expected volatility 80.3 % 83.2% - 87.5% Risk-free rate 4.4 % 4.5% - 4.6% Dividend yield 0 % 0% ( 1 Includes August 2022 March 2022 Note 16

Note 13 - Income Taxes

Note 13 - Income Taxes	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 13 For fiscal 2024 382 June 30, 2024 For fiscal 2023, zero zero June 30, 2023, Section 382 Under the provisions of the IRC, substantial changes in the Company’s ownership have resulted in limitations on the amount of NOL carryforwards that can be utilized in future years. NOL carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is limited to the NOL utilized. Accordingly, the Company may As part of the Company’s Section 382 March 2022 2023 80% June 2023 382 June 30, 2023. 2024, June 2023 382 The Company had federal net operating losses of $519.6 million as of June 30, 2024, 2037. June 30, 2024, 2025 382 not 2025 2039. As of June 30, 2024 The Company notes there is diversity in practice regarding the treatment of deductions or loss carryforwards that are expected to expire unutilized. Generally, it is not zero may zero not zero In review of the Company’s consolidated deferred position, excluding NOLs and other tax attributes, the Company is in a net DTA position and therefore all NOLs are being fully valued and not The provision for income taxes consisted of the following: ​ Year Ended June 30, ​ 2024 2023 ​ (in thousands) Current: ​ ​ Federal $ 1,549 $ 80 State 219 46 Total current tax expense 1,768 126 Deferred: ​ ​ Federal — (109 ) State — (17 ) Total deferred tax expense — (126 ) Provision for income taxes $ 1,768 $ — ​ Income tax expense resulting from applying statutory rates in jurisdictions in which the Company is taxed (federal and various states) differs from the income tax expense in the financial statements. A reconciliation of the United States federal statutory income tax rates to the Company’s effective tax rate is as follows. ​ Year Ended June 30, ​ 2024 2023 ​ (in thousands, except tax rate) Tax at statutory rate $ (2,956 ) 21.0 % $ (3,581 ) 21.0 % State income taxes, net of federal benefit (779 ) 5.5 % (430 ) 2.5 % Stock-based compensation expense 19 (0.1 )% — — % Contingent consideration — — % (193 ) 1.2 % Change in valuation allowance 5,447 (38.7 )% 4,087 (24.0 )% Other 37 (0.3 )% 117 (0.7 )% Net income tax expense $ 1,768 (12.6 )% $ — (0.0 )% ​ Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. The approximate tax effects of significant temporary differences, which comprise the deferred tax assets and liabilities, are as follows: ​ June 30, ​ 2024 2023 ​ (in thousands) Deferred tax assets: ​ ​ Net operating loss carry forward $ 119,170 $ 113,819 Interest 4,845 4,188 Accrued rebates 3,819 6,994 Warrant derivatives 3,061 1,504 Research and development credits 2,416 2,416 Stock-based compensation expense 1,259 4,250 Accrued expenses 1,027 758 Section 174 capitalization 780 836 Inventory 256 743 Lease liability 305 492 Fixed assets 99 — Other 975 1,332 Total deferred tax assets 138,012 137,332 Less: valuation allowance (137,250 ) (135,954 ) Deferred tax assets, net of valuation allowance 762 1,378 Deferred tax liabilities: ​ ​ Intangibles (563 ) (845 ) ROU asset (199 ) (483 ) Fixed assets — (50 ) Total deferred tax liabilities (762 ) (1,378 ) Net deferred tax liabilities $ — $ — The Company has recorded a valuation allowance of $137.3 million and $136.0 million at June 30, 2024, 2023 not not not The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. The Company has no not June 30, 2024, 2023 A tabular roll-forward of the Company’s gross unrecognized tax benefit related to uncertain tax positions is below. ​ June 30, ​ 2024 2023 ​ (in thousands) Beginning balances $ 2,948 $ 2,822 Decrease resulting from current period tax positions (1,996 ) (120 ) Increase resulting from current period tax positions 361 246 Ending balances $ 1,313 $ 2,948 ​ The change in the Company’s gross unrecognized tax benefits relates to filed method changes with the IRS for the tax return year ending June 30, 2023. 2005

Note 14 - Stockholders' Equity

Note 14 - Stockholders' Equity	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Equity [Text Block]	Note 14 Equity The Company has 200.0 million shares of common stock authorized with a par value of $0.0001 per share and 50.0 million shares of preferred stock authorized with a par value of $0.0001 per share. As of June 30, 2024, 2023 June 30, 2024, On June 8, 2020, 3, June 17, 2020. June 4, 2021, 2020 June 30, 2023, 2020 June 2023 July 2023. On September 28, 2021, 3, October 7, 2021. “2021 June 30, 2024, 2021 1.B.6 3. 2021 October 2024. 2021 10 “2024 On March 7, 2022, 2021 “March 2022 one April 2022. six five March 2022 Note 16 On August 11, 2022, “August 2022 2021 one one August 2022. five August 2022 Note 16 On June 8, 2023, “June 2023 may June 2023 one may five 30 200% 40 June 2024 June 2023 not Note 16 On June 14, 2024, Note 11

Note 15 - Equity Incentive Plan

Note 15 - Equity Incentive Plans	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	Note 15 2023 On May 18, 2023, 2023 “2023 2023 2015 2015 2015 2015 2015 “2015 2023 2015 2023 2015 2023 2023 no 2015 2023 June 30, 2024 2023 Aytu 2015 On June 1, 2015, 2015 July 2017, February 13, 2020, 2015 2015 2023 Neos 2015 Pursuant to the Neos Acquisition, the Company assumed 3,486 stock options and 1,786 restricted stock units previously granted under the Neos 2015 April 19, 2021, 2015 2015 Stock Options During the year ended June 30, 2024 June 30, 2024 June 30, 2024 June 30, 2023, June 30, 2023, June 30, 2023, Stock option activity is as follows: ​ ​ Weighted ​ ​ ​ Average ​ ​ Weighted Remaining ​ Number of Average Contractual ​ Options Exercise Price Life in Years Outstanding at June 30, 2023 52,762 $ 18.37 9.1 Granted 113,500 $ 1.74 9.2 Forfeited/cancelled (16,610 ) $ 3.20 — Expired (3,113 ) $ 66.84 — Outstanding at June 30, 2024 146,539 $ 6.18 8.8 ​ ​ ​ ​ Exercisable at June 30, 2024 25,068 $ 26.06 8.0 The following table details the options outstanding at June 30, 2024 ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ ​ ​ Remaining ​ ​ ​ ​ Weighted Contractual ​ ​ Range of Number of Average Life of Number of Weighted Exercise Options Exercise Options Options Average Prices Outstanding Price Outstanding Exercisable Exercise Price $1.73 102,000 $ 1.73 9.1 — $ — $2.53 1,500 $ 2.53 9.6 — $ — $4.00 - $290.00 43,039 $ 16.85 8.1 25,068 $ 225.74 ​ 146,539 $ 6.18 8.8 25,068 $ 225.74 Restricted Stock During the year ended June 30, 2024, 2023 1/3 1/12 first During the year ended June 30, 2023, two On December 19, 2022, 2021 June 30, 2023. During the year ended June 30, 2023, 2015 1/3 1/12 first Restricted stock activity under the 2023 ​ ​ Weighted ​ ​ Average Grant ​ Number of Date Fair ​ Shares Value Unvested at June 30, 2023 38,075 $ 142.20 Granted 12,500 $ 1.77 Vested (25,971 ) $ 113.37 Forfeited/cancelled (499 ) $ 147.15 Unvested at June 30, 2024 24,105 $ 100.34 As of June 30, 2024 June 30, 2024 The Company previously issued 4 shares of restricted stock outside of the Aytu 2015 July 2026. January 17, 2022, 2015 1/3 January 17, 2023, 1/12 January 17, 2025. June 30, 2024 Restricted Stock Units For the years ended June 30, 2024 2023, not ​ ​ Weighted ​ ​ Average Grant ​ Number of Date Fair ​ Shares Value Unvested at June 30, 2023 4,963 $ 25.62 Vested (2,249 ) $ 24.28 Forfeited/cancelled (939 ) $ 31.60 Unvested at June 30, 2024 1,775 $ 24.14 ​ As of June 30, 2024 June 30, 2024 Stock-based compensation expense related to the fair value of stock options, restricted stock and RSUs was included in the consolidated statements of operations as set forth in the below table: ​ Year Ended ​ June 30, ​ 2024 2023 ​ (in thousands) Cost of sales $ 2 $ 28 Research and development 6 30 Selling and marketing — 23 General and administrative 2,905 5,965 Total stock-based compensation expense $ 2,913 $ 6,046

Note 16 - Warrants

Note 16 - Warrants	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Warrants or Rights Disclosure [Text Block]	Note 16 Liability Classified Warrants The Company accounts for liability classified warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of liability classified derivative financial instruments was calculated using either the Black-Scholes option pricing model or the Monte Carlo simulation model and is revalued every quarter. Changes in the fair value of liability classified derivative financial instruments in subsequent periods are recorded as unrealized derivative gain or loss in the consolidated statements of operations. On June 8, 2023, June 2023 may June 2023 one may five 30 200% 40 June 2024 June 2023 not Note 14 On June 14, 2024, not Note 11 On August 11, 2022, August 2022 one one August 2022. five x five 20 16th second Note 14 In November 2022 December 31, 2022, August 2022 January 6, 2023, 1 five twenty December 30, 2022. June 2023, August 2022 On March 7, 2022, one April 2022. six five Note 14 On January 26, 2022, Note 11 June 30, 2022, January 31, 2027. not Note 11 Outstanding warrants that are classified as derivative warrant liabilities in the consolidated balance sheets are marked to market at each reporting period (see Note 12 A summary of warrants is as follows: ​ ​ ​ Weighted ​ ​ ​ Average ​ ​ Weighted Remaining ​ Number of Average Contractual ​ Warrants Exercise Price Life in Years (4) Outstanding June 30, 2023 (1) 6,538,052 $ 4.42 4.7 Warrants issued (2) 1,806,434 $ 0.0001 N/A Warrants exercised (2,247,648 ) $ 1.61 — Warrants expired (20,958 ) $ 300.00 — Outstanding June 30, 2024 (3) 6,075,880 $ 3.71 3.1 ( 1 The number of warrants outstanding as of June 30, 2023, June 2023 ( 2 The warrants issued during fiscal 2024 ( 3 The number of warrants outstanding as of June 30, 2024, June 2023 ( 4 As pre-funded warrants do not

Note 17 - Restructuring Costs

Note 17 - Restructuring Costs	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	Note 17 As part of the Company’s previously announced restructuring activities related to the wind down and divestiture of the Consumer Health Segment and the closure of the Grand Prairie, Texas manufacturing site (Rx Segment), the Company has incurred expenses that qualify as exit and disposal costs under U.S. GAAP. These include severance and employee benefit costs as well as other direct separation benefit costs, right of use asset impairment charges, fixed asset and other asset impairment charges, accelerated depreciation of fixed assets, contract termination costs, and inventory write-downs. Severance and employee benefit costs primarily relate to cash severance. The expense associated with severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations and expense associated with inventory write-downs is recorded in cost of sales in the consolidated statements of operations. The Company does not 2025. June 30, 2024, not June 30, 2024, A summary of restructuring costs incurred during the year ended June 30, 2024, ​ Year Ended June 30, 2024 ​ Severance and Employee Benefits (1) Exit and Disposal Activities (1) Inventory Write-Down (2) Total ​ (in thousands) Wind down of Consumer Health Segment (3) $ 20 $ 189 $ 730 $ 939 Closure of Grand Prairie, Texas manufacturing site (4) 1,125 1,031 — 2,156 Total $ 1,145 $ 1,220 $ 730 $ 3,095 ( 1 Expense associated with severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations. ( 2 Expense associated with inventory write-downs is recorded in cost of sales in the consolidated statements of operations. ( 3 Expense associated with the wind down of the Consumer Health Segment is related to the Consumer Health Segment. ( 4 Expense associated with the closure of the Grand Prairie, Texas manufacturing site is related to the Rx Segment.

Note 18 - Commitments and Conti

Note 18 - Commitments and Contingencies	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 18 Pediatric Portfolio Fixed Payments and Product Milestone The Company assumed two fixed, periodic payment obligations to an investor (the “Fixed Obligation”). Under the first November 1, 2019, January 2021, January 2021 second February 2026, January 2020. On May 29, 2020, first January 2021. On June 21, 2021, second six six September 30, 2021. January 2023. The Company acquired the Tris Karbinal Agreement, under which the Company is granted the exclusive right to distribute and sell Karbinal in the United States. The initial term of the agreement was 20 years. The Company pays Tris a royalty equal to 23.5% of net revenue from the product. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 July 31, 2025. 70,000 2025. August first June 30, 2024, Operating Lease In June 2024, July 2024. March 1, 2025, July 31, 2030, one five July 2035. In May 2023, October 1, 2023, five one five March 2034. Legal Matters Witmer Class-Action Securities Litigation A stockholder derivative suit was filed on September12, 2022, April 5, 2023. 2019 2020 not ​ Sabby Litigation A complaint was filed on February 22, 2023, may October 2023, Stein Litigation Cielo Stein (“Stein”), a former sales specialist, filed a complaint on February 1, 2023, 16 June 3, 2024. August 5, 2024.

Note 19 - License Agreements

Note 19 - License Agreements	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Licensing Agreements [Text Block]	Note 19 Healight In April 2020, ten first As a result of the Company’s focus on the revenue growth of its commercial business, the Company terminated the licensing agreement with Cedars-Sinai Medical Center, effective May 9, 2023. NeuRx In October 2018, 101, NT0502. NT0502 may first In April 2023, NT0502 NT0502. Teva On December 21, 2018, July 1, 2026, June 19, 2020. Actavis On October 17, 2017, September 1, 2025, June 22, 2023. Shire In July 2014, “2014 No. 204326 2014 February 2016. May 2023.

Note 20 - Segment Information

Note 20 - Segment Information	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 20 The Company’s CODM, who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance. The Company manages and aggregates its operational and financial information in accordance with two not not Select financial information for these segments is as follows: Rx Consumer Health Consolidated ​ (in thousands) Year Ended June 30, 2024 ​ ​ ​ ​ ​ ​ ​ Net revenue $ 65,183 $ 15,819 $ 81,002 Loss from operations $ (1,590 ) $ (3,664 ) $ (5,254 ) ​ ​ ​ ​ Depreciation and amortization $ 5,909 $ 1,547 $ 7,456 Stock-based compensation expense $ 2,373 $ 540 $ 2,913 Restructuring costs $ 2,156 $ 209 $ 2,365 ​ ​ ​ ​ Year Ended June 30, 2023 ​ ​ ​ ​ ​ ​ ​ Net revenue $ 73,799 $ 33,600 $ 107,399 Loss from operations $ (7,358 ) $ (9,707 ) $ (17,065 ) ​ ​ ​ ​ Depreciation and amortization $ 6,271 $ 1,116 $ 7,387 Stock-based compensation expense $ 5,722 $ 324 $ 6,046 Impairment expense $ 2,730 $ 2,975 $ 5,705

Note 21 - Subsequent Events

Note 21 - Subsequent Events	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	Note 21 Wind Down and Subsequent Divestiture of Consumer Health Business In July 2024, July 31, 2024, July 31, 2024.

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Jun. 30, 2024
Insider Trading Arr Line Items
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principals of Consolidation The Company’s consolidated financial statements and notes thereto include the accounts of: Aytu Therapeutics, LLC, Innovus Pharmaceuticals, Inc. and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The Company’s consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”)
Going Concern [Policy Text Block]	Going Concern Determination In connection with the preparation for each annual and interim financial reporting period, management evaluates whether there are events that, in the aggregate, raise substantial doubt about the Company’s ability to continue as a going concern within one one Note 1
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results may not
Reclassification, Comparability Adjustment [Policy Text Block]	Prior Period Reclassification . Certain prior year amounts in the Company’s consolidated financial statements and the notes thereto have been reclassified to conform to the current year presentation. These reclassifications did not June 30, 2024, 2023, June 30, 2024 June 30, 2023 Previously Reported Prepaid Expenses Information During the year ended June 30, 2024, June 30, 2023, June 30, 2023. No. 99, not 10
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company’s primary objectives for investment of available cash are the preservation of capital and the maintenance of liquidity. The Company invests its available cash balances in bank deposits and money market funds. The cash balances in bank deposits are subject to the Federal Deposit Insurance Corporation (“FDIC”) insurance limits, and cash balances in the money market funds are not three
Accounts Receivable [Policy Text Block]	Accounts Receivable, Net Accounts receivable represent amounts due from customers less allowances for credit losses, discounts and pricing chargebacks. An allowance for credit losses, when needed, is based on the best estimate of the amount of probable credit losses in existing accounts receivable, which is determined from the Company’s historical write-off experience and expected future default probabilities based on ongoing evaluations of Company’s customers’ financial condition; payment history; collections experience on other accounts; and economic factors or events expected to affect future collections. An allowance for credit losses, when needed, consists of an amount identified for specific customers and an amount based on overall estimated exposure. Accounts receivable are customer obligations due under normal trade terms. Recovery of bad debt amounts which were previously written off are recorded as a reduction of bad debt expense in the period the payment is collected. If the Company’s actual collection experience changes, revisions to the Company’s allowance for credit losses may zero June 30, 2024, 2023. June 30, 2024, 2023, June 30, 2024, 2023. The table below presents the opening and closing balances of accounts receivable, gross from customers. ​ Accounts Receivable, Gross ​ (in thousands) Balance, June 30, 2022 $ 24,219 Increase in accounts receivable, gross 7,708 Balance, June 30, 2023 31,927 Decrease in accounts receivable, gross (6,488 ) Balance, June 30, 2024 $ 25,439 The table below details the change in allowance for discounts and allowance for chargebacks for the periods presented. ​ Allowance for Discounts Allowance for Chargebacks Total Allowance ​ (in thousands) Balances, June 30, 2022 $ 1,301 $ 1,206 $ 2,507 Reduction of net revenue 9,074 4,554 13,628 Payments (8,597 ) (4,548 ) (13,145 ) Balances, June 30, 2023 1,778 1,212 2,990 Reduction of net revenue 4,886 3,812 8,698 Payments (6,024 ) (3,842 ) (9,866 ) Balances, June 30, 2024 $ 640 $ 1,182 $ 1,822
Inventory, Policy [Policy Text Block]	Inventories Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first first The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are no
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at cost less accumulated depreciation. Furniture and equipment are depreciated on a straight-line basis over their estimated useful lives which are generally two seven
Lessee, Leases [Policy Text Block]	Leases At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease. Lease classification, recognition and measurement are determined at the lease commencement date. Lease liabilities and right-of-use (“ROU”) assets are recorded based on the present value of lease payments over the expected lease term, including options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. In determining the present value of the lease payments, the Company uses the implicit interest rate when readily determinable and uses the Company’s incremental borrowing rate when the implicit rate is not Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of sales and operating expenses in the Company’s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of sales and interest expense, respectively, in the Company’s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of 12 Operating leases are included in other liabilities in the Company’s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of debt and debt, net of current portion in the Company’s consolidated balance sheets.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Acquisitions In an acquisition of a business or a group of assets, the Company uses the acquisition method of accounting which identifies, recognizes, and measures the identifiable assets acquired, liabilities assumed and any non-controlling interest at their acquisition date fair values. Any excess of the purchase consideration over the fair values of the net identifiable assets acquired is recorded as goodwill. If the Company determines the assets acquired do not not Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, 480” 815, 815” 480, 480, 815,
Revenue [Policy Text Block]	Revenue Recognition The Company generates revenue from product sales through its Rx Segment and its Consumer Health Segment. The Company evaluates its contracts with customers to determine revenue recognition using the following five 1 2 3 4 5 not Rx Segment Net product sales for the Rx Segment (which includes the ADHD Portfolio and the Pediatric Portfolio) consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx Segment net revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally “free-on-board” destination when shipped domestically within the United States and “free-on-board” shipping point when shipped internationally consistent with the contractual terms. The Company expenses the incremental costs to obtain a contract as incurred, since they are satisfied within one Rx Segment net revenue is recognized net of consideration paid to the Company’s customers and other adjustments to the transaction price (known as “Gross to Net” adjustments). Significant judgement is required in estimating Gross to Net adjustments considering legal interpretations of applicable laws and regulations, historical experience, payer channel mix, current contract prices under applicable programs, unbilled claims, processing time lags and inventory levels in the distribution channel. The Gross to Net adjustments include: ● Savings offers. ● Prompt payment discounts. ● Wholesale distribution fees. ● Rebates. third ● Wholesaler chargebacks. ● Returns. six twelve Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which may may not not Consumer Health Segment The Consumer Health Segment, which was divested of in the first 2025, one
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk . Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents and accounts receivable. The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is not The Company is also subject to credit risk from accounts receivable related to product sales. The Company’s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company’s products to retailers. The loss of one not thirty sixty The following table presents customers that contributed more than 10% : ​ Percentage of Gross Revenue Percentage of Accounts Receivable ​ June 30, June 30, ​ 2024 2023 2024 2023 Customer A 33 % 43 % 40 % 50 % Customer B 20 % 18 % 29 % 19 % Customer C 17 % 17 % 11 % 14 %
Cost of Goods and Service [Policy Text Block]	Costs of Sales Costs of sales consists primarily of manufactured product cost, products acquired from third may third
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation Expense The Company accounts for stock-based payment compensation expense using a fair value based model. Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company’s common stock and recognized ratably over the requisite service period. Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the “simplified method,” which is the midpoint between the vesting date and the end of the contractual term and is utilized by the Company as it does not not
Pension and Other Postretirement Plans, Policy [Policy Text Block]	Employee Benefits Plan The Company has a 401 401 401 first 401 June 30, 2024, 2023.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are expensed as incurred and include salaries and benefits; facilities costs; overhead costs; raw materials; laboratory and clinical supplies; clinical trial costs; contract services; milestone payments and fees paid to regulatory authorities for review and approval of the Company’s product candidates; and other related costs.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets The Company records acquired intangible assets based on fair value on the date of acquisition. Finite-lived intangible assets are recorded at cost and amortized on a straight-line basis over the estimated lives of the assets. Indefinite-lived intangible assets are not
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-lived Assets The Company assesses impairment of asset groups, including intangible assets, when events or changes in circumstances indicate that their carrying amount may not not not
Business Combinations, Contingent Consideration [Policy Text Block]	Contingent Consideration The consideration for the Company's acquired businesses and licenses often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income, which resulted in a gain from contingent consideration of zero June 30, 2024, 2023, not June 30, 2024, 2023.
Advertising Cost [Policy Text Block]	Advertising and Direct Marketing Costs Advertising and direct marketing costs consist of the direct marketing activities related to the Consumer Health Segment. The Company expenses all advertising costs as incurred. The Company incurred $4.9 million and $17.2 million of advertising costs for the years ended June 30, 2024, 2023
Income Tax, Policy [Policy Text Block]	Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not not The Company recognizes the effect of income tax positions only if those positions are more likely than not
Debt, Policy [Policy Text Block]	Debt Discount and Issuance Costs Debt issuance costs reflect fees paid to lenders and third
Segment Reporting, Policy [Policy Text Block]	Segment Information The Company’s operating segments engage in business activities from which it may two
Legal Costs, Policy [Policy Text Block]	Paragraph IV Litigation Costs Legal costs incurred by the Company in the enforcement of the Company’s intellectual property rights are charged to expense.
Business Combinations Policy [Policy Text Block]	Business Combinations The Company recognizes the identifiable tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The excess of purchase price over the aggregate fair values is recorded as goodwill. The Company calculates the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed to allocate the purchase price at the acquisition date.
Employee Retention Credit [Policy Text Block]	Employee Retention Credit On March 27, 2020, 19 70% December 31, 2020, September 30, 2021. 19 As there is no 20, 20” 20, first 2024. 20, 1986, first 2024.
Earnings Per Share, Policy [Policy Text Block]	Net Income (Loss) Per Share Basic net income (loss) per share is calculated by dividing the net income (loss) available to the common stockholders by the weighted average number of common shares outstanding during that period. Diluted net income (loss) per share reflects the potential of securities that could share in the net income (loss) of the Company. For the years ended June 30, 2024, 2023 not The following table sets forth securities excluded from the calculation of diluted earnings per share. ​ ​ ​ June 30, ​ ​ 2024 2023 Warrants to purchase common stock - liability classified (Note 16) 6,057,766 6,498,980 Warrants to purchase common stock - equity classified (Note 16) 18,114 39,072 Employee stock options (Note 15) 146,539 52,762 Employee unvested restricted stock (Note 15) 25,360 40,996 Employee unvested restricted stock units (Note 15) 1,775 4,963 Total ​ 6,249,554 6,636,773
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements Financial Instruments - Credit Losses In June 2016, No. 2016 13, Financial Instruments—Credit Losses 2016 13” 2016 13 December 15, 2019. October 2019, December 15, 2022. 2022 02 2016 13. 2016 13 2019 05 July 1, 2023. 2016 13, 2019 05, 2022 02 not Recent Accounting Pronouncements Not Debt Debt with Conversion and Other Options In August 2020, No. 2020 06, Debt—Debt with Conversion and Other Options (Subtopic 470 20 815 40 no December 15, 2023, July 1, 2024, not Segment Reporting In November 2023, No. 2023 07, Segment Reporting (Topic 280 2023 07” 2023 07 2023 07 December 15, 2023, December 15, 2024. Other than the application of IAS 20 no no not June 30, 2024 10

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	​ Accounts Receivable, Gross ​ (in thousands) Balance, June 30, 2022 $ 24,219 Increase in accounts receivable, gross 7,708 Balance, June 30, 2023 31,927 Decrease in accounts receivable, gross (6,488 ) Balance, June 30, 2024 $ 25,439
Accounts Receivable, Allowance for Credit Loss [Table Text Block]	​ Allowance for Discounts Allowance for Chargebacks Total Allowance ​ (in thousands) Balances, June 30, 2022 $ 1,301 $ 1,206 $ 2,507 Reduction of net revenue 9,074 4,554 13,628 Payments (8,597 ) (4,548 ) (13,145 ) Balances, June 30, 2023 1,778 1,212 2,990 Reduction of net revenue 4,886 3,812 8,698 Payments (6,024 ) (3,842 ) (9,866 ) Balances, June 30, 2024 $ 640 $ 1,182 $ 1,822
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	​ Percentage of Gross Revenue Percentage of Accounts Receivable ​ June 30, June 30, ​ 2024 2023 2024 2023 Customer A 33 % 43 % 40 % 50 % Customer B 20 % 18 % 29 % 19 % Customer C 17 % 17 % 11 % 14 %
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	​ ​ June 30, ​ ​ 2024 2023 Warrants to purchase common stock - liability classified (Note 16) 6,057,766 6,498,980 Warrants to purchase common stock - equity classified (Note 16) 18,114 39,072 Employee stock options (Note 15) 146,539 52,762 Employee unvested restricted stock (Note 15) 25,360 40,996 Employee unvested restricted stock units (Note 15) 1,775 4,963 Total ​ 6,249,554 6,636,773

Note 3 - Revenue (Tables)

Note 3 - Revenue (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	​ Year Ended ​ June 30, ​ 2024 2023 ​ (in thousands) Rx Segment net revenue $ 65,183 $ 73,799 Consumer Health Segment net revenue 15,819 33,600 Total net revenue $ 81,002 $ 107,399 ​ Year Ended ​ June 30, ​ 2024 2023 (in thousands) ADHD Portfolio net revenue $ 57,784 $ 46,855 Pediatric Portfolio net revenue 7,280 25,377 Other 119 1,567 Total Rx Segment net revenue $ 65,183 $ 73,799
Revenue from External Customers by Geographic Areas [Table Text Block]	​ Year Ended ​ June 30, ​ 2024 2023 ​ (in thousands) United States net revenue $ 80,911 $ 106,918 International net revenue 91 481 Total net revenue $ 81,002 $ 107,399

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	​ June 30, ​ 2024 2023 ​ (in thousands) Raw materials $ 266 $ 1,301 Work in process 5,725 2,956 Finished goods 6,642 7,738 Inventories $ 12,633 $ 11,995

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	​ June 30, ​ 2024 2023 ​ (in thousands) Manufacturing equipment $ 1,117 $ 2,433 Office equipment, furniture and other 945 1,125 Lab equipment 721 832 Leasehold improvements 35 999 Assets under construction — 107 Property and equipment, gross 2,818 5,496 Less accumulated depreciation and amortization (2,125 ) (3,681 ) Property and equipment, net $ 693 $ 1,815

Note 6 - Leases (Tables)

Note 6 - Leases (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Lease, Cost [Table Text Block]	​ Year Ended ​ ​ June 30, ​ ​ 2024 2023 Statement of Operations Classification ​ (in thousands) ​ Lease cost: ​ ​ ​ Operating lease cost $ 2,247 $ 1,402 Operating expenses Short-term lease cost 94 97 Operating expenses Finance lease cost: ​ ​ ​ Amortization of leased assets 53 66 Cost of sales Interest on lease liabilities 3 9 Interest expense Total lease cost $ 2,397 $ 1,574 ​ June 30, ​ 2024 2023 Weighted-average remaining lease term (years): ​ ​ Operating lease assets 2.7 1.7 Finance lease assets — 0.9 Weighted-average discount rate: ​ ​ Operating lease assets 10.0 % 7.8 % Finance lease assets — % 6.5 % ​ Year Ended ​ June 30, ​ 2024 2023 ​ (in thousands) Cash flow classification of lease payments: ​ ​ Operating cash flows from operating leases $ 1,812 $ 1,436 Operating cash flows from finance leases $ 3 $ 9 Financing cash flows from finance leases $ 85 $ 96
Schedule of Lease by Balance Sheet Information [Table Text Block]	​ June 30, ​ 2024 2023 Balance Sheet Classification ​ (in thousands) ​ Assets: ​ ​ ​ Operating lease assets $ 829 $ 2,054 Operating lease right-of-use assets Finance lease assets — 159 Property and equipment, net Total lease assets $ 829 $ 2,213 ​ Liabilities: ​ ​ ​ Current: ​ ​ ​ Operating leases $ 712 $ 1,258 Other current liabilities Finance leases — 85 Current portion of debt Non-current: ​ ​ ​ Operating leases 577 832 Other liabilities Total lease liabilities $ 1,289 $ 2,175 ​
Lessee, Liability, Maturity [Table Text Block]	​ Operating ​ (in thousands) 2025 $ 970 2026 399 2027 377 2028 386 2029 359 Thereafter 249 Total lease payments 2,740 Less: imputed interest (555 ) Lease liabilities $ 2,185

Note 7 - Intangible Assets (Tab

Note 7 - Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	​ June 30, 2024 ​ Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted-Average Remaining Life ​ (in thousands) (in years) Acquired product technology rights $ 41,268 $ (13,184 ) $ 28,084 10.5 Acquired technology rights 30,200 (5,831 ) 24,369 13.8 Total definite-lived intangible assets $ 71,468 $ (19,015 ) $ 52,453 12.0 ​ June 30, 2023 ​ Gross Carrying Amount Accumulated Amortization Net Carrying Amount Weighted-Average Remaining Life ​ (in thousands) (in years) Acquired product technology rights $ 42,176 $ (10,881 ) $ 31,295 11.5 Acquired technology rights 30,200 (4,054 ) 26,146 14.8 Acquired product distribution rights 6,207 (4,678 ) 1,529 1.0 Total definite-lived intangible assets $ 78,583 $ (19,613 ) $ 58,970 12.7
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	​ June 30, ​ (in thousands) 2025 $ 4,989 2026 4,989 2027 4,989 2028 4,989 2029 4,989 Thereafter 27,508 Total future amortization expense $ 52,453

Note 8 - Accrued Liabilities (T

Note 8 - Accrued Liabilities (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	​ June 30, ​ 2024 2023 ​ (in thousands) Accrued savings offers $ 11,054 $ 15,739 Accrued program liabilities 9,964 11,012 Accrued customer and product related fees 5,395 6,579 Accrued compensation 4,935 5,675 Return reserve 4,835 5,777 Other accrued liabilities 2,391 2,017 Total accrued liabilities $ 38,574 $ 46,799
Summary of Valuation Allowance [Table Text Block]	​ Return Reserve ​ (in thousands) Balance, June 30, 2022 $ 5,770 Reduction of net revenue 8,353 Payments (8,346 ) Balance, June 30, 2023 5,777 Reduction of net revenue 6,128 Payments (7,070 ) Balance, June 30, 2024 $ 4,835

Note 9 - Other Liabilities (Tab

Note 9 - Other Liabilities (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Other Liabilities [Table Text Block]	​ June 30, ​ 2024 2023 ​ (in thousands) Fixed payment arrangements $ 8,337 $ 10,420 Employee retention credit 3,759 — Operating lease liabilities 1,289 2,090 Other 106 1,555 Total other liabilities 13,491 14,065 Less: current portion of other liabilities (8,962 ) (7,090 ) Total other liabilities, non-current $ 4,529 $ 6,975

Note 11 - Long-term Debt (Table

Note 11 - Long-term Debt (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Long-Term Debt Instruments [Table Text Block]	​ June 30, ​ 2024 2023 ​ (in thousands) Term loan principal amount $ 13,000 $ 15,000 Unamortized debt discount and issuance costs (266 ) (925 ) Final payment fee — 638 Financing leases — 85 Total debt 12,734 14,798 Less: current portion of debt (1,857 ) (85 ) Total debt, net of current portion $ 10,877 $ 14,713
Schedule of Maturities of Long-Term Debt [Table Text Block]	​ June 30, ​ (in thousands) 2025 $ 1,857 2026 1,857 2027 1,857 2028 7,429 Total future term loan principal payments 13,000 Less: unamortized debt discount and issuance costs (266 ) Less: current portion of debt (1,857 ) Total debt, net of current portion $ 10,877

Note 12 - Fair Value Measurem_2

Note 12 - Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	​ Fair Value at Fair Value Measurements at June 30, 2024 ​ June 30, 2024 (Level 1) (Level 2) (Level 3) ​ (in thousands) Liabilities: ​ ​ ​ ​ Derivative warrant liabilities $ 12,745 $ — $ — $ 12,745 Total $ 12,745 $ — $ — $ 12,745 ​ Fair Value at Fair Value Measurements at June 30, 2023 ​ June 30, 2023 (Level 1) (Level 2) (Level 3) ​ (in thousands) Liabilities: ​ ​ ​ ​ Derivative warrant liabilities $ 6,403 $ — $ — $ 6,403 Total $ 6,403 $ — $ — $ 6,403
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	​ Derivative Warrant ​ Liabilities ​ (in thousands) Balance as of June 30, 2022 $ 1,796 Issued 10,998 Settlements — Included in earnings (6,391 ) Balance as of June 30, 2023 6,403 Issued (1) 5,148 Settlements (1) (2,810 ) Included in earnings 4,004 Balance as of June 30, 2024 $ 12,745
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	​ June 2023 Warrants Warrants ​ Tranche A Other (1) Monte Carlo & Black-Scholes Black-Scholes Aytu closing stock price $ 2.92 $ 2.92 Equivalent term (years) 3.9 2.6 - 3.2 Expected volatility 80.3 % 83.2% - 87.5% Risk-free rate 4.4 % 4.5% - 4.6% Dividend yield 0 % 0%

Note 13 - Income Taxes (Tables)

Note 13 - Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	​ Year Ended June 30, ​ 2024 2023 ​ (in thousands) Current: ​ ​ Federal $ 1,549 $ 80 State 219 46 Total current tax expense 1,768 126 Deferred: ​ ​ Federal — (109 ) State — (17 ) Total deferred tax expense — (126 ) Provision for income taxes $ 1,768 $ —
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	​ Year Ended June 30, ​ 2024 2023 ​ (in thousands, except tax rate) Tax at statutory rate $ (2,956 ) 21.0 % $ (3,581 ) 21.0 % State income taxes, net of federal benefit (779 ) 5.5 % (430 ) 2.5 % Stock-based compensation expense 19 (0.1 )% — — % Contingent consideration — — % (193 ) 1.2 % Change in valuation allowance 5,447 (38.7 )% 4,087 (24.0 )% Other 37 (0.3 )% 117 (0.7 )% Net income tax expense $ 1,768 (12.6 )% $ — (0.0 )%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	​ June 30, ​ 2024 2023 ​ (in thousands) Deferred tax assets: ​ ​ Net operating loss carry forward $ 119,170 $ 113,819 Interest 4,845 4,188 Accrued rebates 3,819 6,994 Warrant derivatives 3,061 1,504 Research and development credits 2,416 2,416 Stock-based compensation expense 1,259 4,250 Accrued expenses 1,027 758 Section 174 capitalization 780 836 Inventory 256 743 Lease liability 305 492 Fixed assets 99 — Other 975 1,332 Total deferred tax assets 138,012 137,332 Less: valuation allowance (137,250 ) (135,954 ) Deferred tax assets, net of valuation allowance 762 1,378 Deferred tax liabilities: ​ ​ Intangibles (563 ) (845 ) ROU asset (199 ) (483 ) Fixed assets — (50 ) Total deferred tax liabilities (762 ) (1,378 ) Net deferred tax liabilities $ — $ —
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	​ June 30, ​ 2024 2023 ​ (in thousands) Beginning balances $ 2,948 $ 2,822 Decrease resulting from current period tax positions (1,996 ) (120 ) Increase resulting from current period tax positions 361 246 Ending balances $ 1,313 $ 2,948

Note 15 - Equity Incentive Pl_2

Note 15 - Equity Incentive Plans (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	​ ​ Weighted ​ ​ ​ Average ​ ​ Weighted Remaining ​ Number of Average Contractual ​ Options Exercise Price Life in Years Outstanding at June 30, 2023 52,762 $ 18.37 9.1 Granted 113,500 $ 1.74 9.2 Forfeited/cancelled (16,610 ) $ 3.20 — Expired (3,113 ) $ 66.84 — Outstanding at June 30, 2024 146,539 $ 6.18 8.8 ​ ​ ​ ​ Exercisable at June 30, 2024 25,068 $ 26.06 8.0
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	​ ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ ​ ​ Remaining ​ ​ ​ ​ Weighted Contractual ​ ​ Range of Number of Average Life of Number of Weighted Exercise Options Exercise Options Options Average Prices Outstanding Price Outstanding Exercisable Exercise Price $1.73 102,000 $ 1.73 9.1 — $ — $2.53 1,500 $ 2.53 9.6 — $ — $4.00 - $290.00 43,039 $ 16.85 8.1 25,068 $ 225.74 ​ 146,539 $ 6.18 8.8 25,068 $ 225.74
Nonvested Restricted Stock Shares Activity [Table Text Block]	​ ​ Weighted ​ ​ Average Grant ​ Number of Date Fair ​ Shares Value Unvested at June 30, 2023 38,075 $ 142.20 Granted 12,500 $ 1.77 Vested (25,971 ) $ 113.37 Forfeited/cancelled (499 ) $ 147.15 Unvested at June 30, 2024 24,105 $ 100.34
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	​ ​ Weighted ​ ​ Average Grant ​ Number of Date Fair ​ Shares Value Unvested at June 30, 2023 4,963 $ 25.62 Vested (2,249 ) $ 24.28 Forfeited/cancelled (939 ) $ 31.60 Unvested at June 30, 2024 1,775 $ 24.14
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]	​ Year Ended ​ June 30, ​ 2024 2023 ​ (in thousands) Cost of sales $ 2 $ 28 Research and development 6 30 Selling and marketing — 23 General and administrative 2,905 5,965 Total stock-based compensation expense $ 2,913 $ 6,046

Note 16 - Warrants (Tables)

Note 16 - Warrants (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	​ ​ ​ Weighted ​ ​ ​ Average ​ ​ Weighted Remaining ​ Number of Average Contractual ​ Warrants Exercise Price Life in Years (4) Outstanding June 30, 2023 (1) 6,538,052 $ 4.42 4.7 Warrants issued (2) 1,806,434 $ 0.0001 N/A Warrants exercised (2,247,648 ) $ 1.61 — Warrants expired (20,958 ) $ 300.00 — Outstanding June 30, 2024 (3) 6,075,880 $ 3.71 3.1

Note 17 - Restructuring Costs (

Note 17 - Restructuring Costs (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Restructuring and Related Costs [Table Text Block]	​ Year Ended June 30, 2024 ​ Severance and Employee Benefits (1) Exit and Disposal Activities (1) Inventory Write-Down (2) Total ​ (in thousands) Wind down of Consumer Health Segment (3) $ 20 $ 189 $ 730 $ 939 Closure of Grand Prairie, Texas manufacturing site (4) 1,125 1,031 — 2,156 Total $ 1,145 $ 1,220 $ 730 $ 3,095

Note 20 - Segment Information (

Note 20 - Segment Information (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Rx Consumer Health Consolidated ​ (in thousands) Year Ended June 30, 2024 ​ ​ ​ ​ ​ ​ ​ Net revenue $ 65,183 $ 15,819 $ 81,002 Loss from operations $ (1,590 ) $ (3,664 ) $ (5,254 ) ​ ​ ​ ​ Depreciation and amortization $ 5,909 $ 1,547 $ 7,456 Stock-based compensation expense $ 2,373 $ 540 $ 2,913 Restructuring costs $ 2,156 $ 209 $ 2,365 ​ ​ ​ ​ Year Ended June 30, 2023 ​ ​ ​ ​ ​ ​ ​ Net revenue $ 73,799 $ 33,600 $ 107,399 Loss from operations $ (7,358 ) $ (9,707 ) $ (17,065 ) ​ ​ ​ ​ Depreciation and amortization $ 6,271 $ 1,116 $ 7,387 Stock-based compensation expense $ 5,722 $ 324 $ 6,046 Impairment expense $ 2,730 $ 2,975 $ 5,705

Note 1 - Nature of Business a_2

Note 1 - Nature of Business and Financial Condition (Details Textual) $ in Millions	12 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023
Number of Operating Segments		2
Line of Credit Facility, Remaining Borrowing Capacity	$ 5.6
Proceeds from Warrant Exercises	3.5
Avenue Capital Loan [Member]
Extinguishment of Debt, Amount	15
Eclipse Term loan [Member]
Proceeds from Issuance of Debt	13
Maximum [Member]
Revenue-based Royalty Costs	$ 0.5

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Thousands	3 Months Ended	10 Months Ended	12 Months Ended
	Mar. 31, 2024 USD ($)	Apr. 29, 2024	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)
Prepaid Expense, Current			$ 5,635	$ 7,162
Accounts Receivable, Allowance for Credit Loss			0	0
Accounts Receivable, Allowance for Discounts			640	1,778	$ 1,301
Accounts Receivable, Allowance for Pricing Chargebacks			1,182	1,212	$ 1,206
Defined Contribution Plan, Employer Discretionary Contribution Amount			700
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			0	(969)
Advertising Expense			$ 4,900	17,200
Number of Reportable Segments		2	2
Employee Retention Credit			$ 3,759	0
Employee Retention Credit, Vendor Fee	$ 400
Other Noncurrent Liabilities [Member]
Employee Retention Credit	$ 3,800		$ 3,800
Neos Plan [Member] | First Three Percent Contribution By Employees [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match			100%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay			3%
Neos Plan [Member] | Next Four Percent and Five Percent Contribution By Employees [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match			50%
Neos Plan [Member] | Next Four Percent Contribution By Employees [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay			4%
Neos Plan [Member] | Next Five Percent Contribution By Employees [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay			5%
Minimum [Member]
Accounts Receivable, Credit Terms (Day)			30 days
Maximum [Member]
Accounts Receivable, Credit Terms (Day)			60 days
Furniture and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)			2 years
Furniture and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)			7 years
Immaterial Error Correction of Prepaid Expenses from Current Asset to Noncurrent Asset [Member] | Previously Reported [Member]
Prepaid Expense, Current				$ 1,800

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Balance	$ 31,927	$ 24,219
Increase (decrease) in accounts receivable, gross	(6,488)	7,708
Balance	$ 25,439	$ 31,927

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Allowance for Credit Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Balance, allowance for discount	$ 1,778	$ 1,301
Balance, allowance for chargeback	1,212	1,206
Balance	2,990	2,507
Reduction of net revenue, allowance for discount	4,886	9,074
Reduction of net revenue, allowance for chargeback	3,812	4,554
Reduction of net revenue	8,698	13,628
Payments, allowance for discount	(6,024)	(8,597)
Payments, allowance for chargeback	(3,842)	(4,548)
Payments	(9,866)	(13,145)
Reduction of net revenue	8,698	13,628
Balance, allowance for discount	640	1,778
Balance, allowance for chargeback	1,182	1,212
Balance	$ 1,822	$ 2,990

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) - Customer Concentration Risk [Member]	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Customer A [Member] | Revenue from Contract with Customer Benchmark [Member]
Customer concentration risk	33%	43%
Customer A [Member] | Accounts Receivable [Member]
Customer concentration risk	40%	50%
Customer B [Member] | Revenue from Contract with Customer Benchmark [Member]
Customer concentration risk	20%	18%
Customer B [Member] | Accounts Receivable [Member]
Customer concentration risk	29%	19%
Customer C [Member] | Revenue from Contract with Customer Benchmark [Member]
Customer concentration risk	17%	17%
Customer C [Member] | Accounts Receivable [Member]
Customer concentration risk	11%	14%

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Securities Excluded from Calculation of Earnings Per Share (Details) - shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Securites excluded (in shares)	6,249,554	6,636,773
Liability Warrants [Member]
Securites excluded (in shares)	6,057,766	6,498,980
Equity Warrants [Member]
Securites excluded (in shares)	18,114	39,072
Share-Based Payment Arrangement, Option [Member]
Securites excluded (in shares)	146,539	52,762
Restricted Stock [Member]
Securites excluded (in shares)	25,360	40,996
Restricted Stock Units (RSUs) [Member]
Securites excluded (in shares)	1,775	4,963

Note 3 - Revenue (Details Textu

Note 3 - Revenue (Details Textual)	10 Months Ended	12 Months Ended
	Apr. 29, 2024	Jun. 30, 2024
Number of Reportable Segments	2	2
Consumer Health [Member] | Minimum [Member]
Number of Products		10

Note 3 - Revenue - Disaggregati

Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Revenue	$ 81,002	$ 107,399
Rx Segment [Member]
Revenue	65,183	73,799
Rx Segment [Member] | ADHD Portfolio [Member]
Revenue	57,784	46,855
Rx Segment [Member] | The Pediatric Portfolio [Member]
Revenue	7,280	25,377
Rx Segment [Member] | Product and Service, Other [Member]
Revenue	119	1,567
Consumer Health [Member]
Revenue	$ 15,819	$ 33,600

Note 3 - Revenue - Revenue by G

Note 3 - Revenue - Revenue by Geographic Location (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Revenue	$ 81,002	$ 107,399
UNITED STATES
Revenue	80,911	106,918
Non-US [Member]
Revenue	$ 91	$ 481

Note 4 - Inventories (Details T

Note 4 - Inventories (Details Textual) - USD ($) $ in Thousands		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Inventory Write-down		$ 2,270	$ 2,351
Restructuring Costs		3,095
Inventory Write Downs [Member]
Restructuring Costs	[1]	730
Inventory Write Downs [Member] | Consumer Health Segment [Member]
Restructuring Costs	[1],[2]	$ 730
[1]Expense associated with inventory write-downs is recorded in cost of sales in the consolidated statements of operations.[2]Expense associated with the wind down of the Consumer Health Segment is related to the Consumer Health Segment.

Note 4 - Inventories - Schedule

Note 4 - Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Raw materials	$ 266	$ 1,301
Work in process	5,725	2,956
Finished goods	6,642	7,738
Inventories	$ 12,633	$ 11,995

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Depreciation	$ 900	$ 1,300
Gain (Loss) on Disposition of Property Plant Equipment	$ 0	$ 100

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Property and equipment, gross	$ 2,818	$ 5,496
Less accumulated depreciation and amortization	(2,125)	(3,681)
Property and equipment, net	693	1,815
Manufacturing Equipment [Member]
Property and equipment, gross	1,117	2,433
Office Equipment, Furniture and Other [Member]
Property and equipment, gross	945	1,125
Lab Equipment [Member]
Property and equipment, gross	721	832
Leasehold Improvements [Member]
Property and equipment, gross	35	999
Asset under Construction [Member]
Property and equipment, gross	$ 0	$ 107

Note 6 - Leases (Details Textua

Note 6 - Leases (Details Textual) - USD ($)	Jun. 30, 2024	Jun. 30, 2023	May 31, 2023	Mar. 19, 2021	Feb. 28, 2015
Finance Lease, Liability	$ 0	$ 85,000
Operating Lease, Right-of-Use Asset	829,000	2,054,000
Operating Lease, Liability	1,289,000	$ 2,090,000
Office Space And Manufacturing Facilities Grand Prairie Texas [Member]
Operating Lease, Right-of-Use Asset				$ 3,500,000
Lessee, Operating Lease, Discount Rate				6.70%
Operating Lease, Liability				$ 3,500,000
Office Space in Berwyn, Pennsylvania [Member]
Operating Lease, Right-of-Use Asset	$ 500,000
Lessee, Operating Lease, Discount Rate	12.30%
Operating Lease, Undiscounted Minimum Monthly Payment	$ 13,000
Operating Lease, Liability	$ 500,000
Principal Office Denver Colorado [Member]
Operating Lease, Right-of-Use Asset			$ 800,000
Lessee, Operating Lease, Discount Rate			10.30%
Operating Lease, Undiscounted Minimum Monthly Payment			$ 15,500
Operating Lease, Liability			$ 800,000
Lessee, Operating Lease, Term of Contract (Year)			5 years 6 months		5 years

Note 6 - Leases - Lease Cost (D

Note 6 - Leases - Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Total lease cost	$ 2,397	$ 1,574
Operating lease assets (Year)	2 years 8 months 12 days	1 year 8 months 12 days
Finance lease assets (Year)		10 months 24 days
Operating lease assets	10%	7.80%
Finance lease assets	0%	6.50%
Operating cash flows from operating leases	$ 1,812	$ 1,436
Operating cash flows from finance leases	3	9
Financing cash flows from finance leases	85	96
Operating Expense [Member]
Operating lease cost	2,247	1,402
Short-term lease cost	94	97
Cost of Sales [Member]
Amortization of leased assets	53	66
Other Expense [Member]
Interest on lease liabilities	$ 3	$ 9

Note 6 - Leases - Lease Balance

Note 6 - Leases - Lease Balance Sheet Information (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Operating lease right-of-use assets	$ 829	$ 2,054
Finance lease assets	0	159
Total lease assets	829	2,213
Operating leases, current	712	1,258
Finance leases, current	0	85
Operating leases, non-current	577	832
Total lease liabilities	$ 1,289	$ 2,175

Note 6 - Leases - Lease Balan_2

Note 6 - Leases - Lease Balance Sheet Information (Details) (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Assets [Abstract]
Property, Plant and Equipment, Net	$ 693	$ 1,815
Liabilities, Current [Abstract]
Other Liabilities, Current	8,962	7,090
Long-Term Debt, Current Maturities	1,857	85
Liabilities, Noncurrent [Abstract]
Liabilities, Noncurrent	28,151	28,091
Other Liabilities, Noncurrent	$ 4,529	$ 6,975
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, Plant and Equipment, Net	Property, Plant and Equipment, Net
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Current	Other Liabilities, Current
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Long-Term Debt, Current Maturities	Long-Term Debt, Current Maturities
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Noncurrent	Other Liabilities, Noncurrent

Note 6 - Leases - Schedule of L

Note 6 - Leases - Schedule of Lease Liability Maturity (Details) $ in Thousands	Jun. 30, 2024 USD ($)
2025	$ 970
2026	399
2027	377
2028	386
2029	359
Thereafter	249
Total lease payments	2,740
Less: imputed interest	(555)
Lease liabilities	$ 2,185

Note 7 - Intangible Assets (Det

Note 7 - Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Asset Impairment Charges		$ 0	$ 5,705
Goodwill			0
Amortization Expense of Intangible Assets		$ 6,500	$ 6,100
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]			Asset Impairment Charges
Impairment of Intangible Assets, Finite-Lived			$ 3,000
Neos Therapeutics, Inc. [Member]
Impairment of Intangible Assets, Finite-Lived	$ 2,600
Patented Technology [Member] | ADHD Portfolio [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			16 years
Tris Karbinal Agreement [Member]
Supply and Distribution Agreement, Extension Term (Year)			20 years
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year)		1 year
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life, Renewable Period (Year)		20 years

Note 7 - Intangible Assets - Sc

Note 7 - Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Finite-lived intangible assets, gross	$ 71,468	$ 78,583
Finite-lived intangible assets, amortization	(19,015)	(19,613)
Finite-lived intangible assets, net	$ 52,453	$ 58,970
Finite-lived intangible assets, remaining life (Year)	12 years	12 years 8 months 12 days
Technology-Based Intangible Assets [Member]
Finite-lived intangible assets, gross	$ 41,268	$ 42,176
Finite-lived intangible assets, amortization	(13,184)	(10,881)
Finite-lived intangible assets, net	$ 28,084	$ 31,295
Finite-lived intangible assets, remaining life (Year)	10 years 6 months	11 years 6 months
Developed Technology Rights [Member]
Finite-lived intangible assets, gross	$ 30,200	$ 30,200
Finite-lived intangible assets, amortization	(5,831)	(4,054)
Finite-lived intangible assets, net	$ 24,369	$ 26,146
Finite-lived intangible assets, remaining life (Year)	13 years 9 months 18 days	14 years 9 months 18 days
Distribution Rights [Member]
Finite-lived intangible assets, gross		$ 6,207
Finite-lived intangible assets, amortization		(4,678)
Finite-lived intangible assets, net		$ 1,529
Finite-lived intangible assets, remaining life (Year)		1 year

Note 7 - Intangible Assets - Fu

Note 7 - Intangible Assets - Future Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
2025, future amortization expense	$ 4,989
2026, future amortization expense	4,989
2027, future amortization expense	4,989
2028, future amortization expense	4,989
2029, future amortization expense	4,989
Thereafter, future amortization expense	27,508
Total future amortization expense	$ 52,453	$ 58,970

Note 8 - Accrued Liabilities -

Note 8 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Accrued savings offers	$ 11,054	$ 15,739
Accrued program liabilities	9,964	11,012
Accrued customer and product related fees	5,395	6,579
Accrued compensation	4,935	5,675
Return reserve	4,835	5,777
Other accrued liabilities	2,391	2,017
Total accrued liabilities	$ 38,574	$ 46,799

Note 8 - Accrued Liabilities _2

Note 8 - Accrued Liabilities - Schedule of Return Reserve (Details) - SEC Schedule, 12-09, Reserve, Return [Member] - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Balance	$ 5,777	$ 5,770
Reduction of net revenue	6,128	8,353
Payments	(7,070)	(8,346)
Balance	$ 4,835	$ 5,777

Note 9 - Other Liabilities (Det

Note 9 - Other Liabilities (Details Textual)	12 Months Ended
	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Jun. 30, 2023 USD ($)
Fixed Payment Arrangements	$ 8,337,000		$ 10,420,000
Employee Retention Credit	3,759,000		$ 0
Business Combination, Contingent Consideration, Liability	0
Other Noncurrent Liabilities [Member]
Employee Retention Credit	3,800,000	$ 3,800,000
Tris License Agreement [Member] | Other Current Liabilities [Member]
Settlement Liabilities, Current	$ 6,200,000
Tris Karbinal Agreement [Member]
Supply and Distribution Commitment, Period (Year)	20 years
Supply and Distribution Commitment, Royalty, Percentage of Net Sales	23.50%
Supply and Distribution Agreement, Minimum Sales Per Year	70,000
Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit	$ 30
Supply and Distribution Agreement, Maximum Yearly Make-whole Payment	2,100,000
Supply and Distribution Agreement, Maximum Milestone Obligations	3,000,000
Supply and Distribution Agreement, First Milestone, Minimum Net Revenues	40,000,000
Tris Karbinal Agreement [Member] | Other Current Liabilities [Member]
Fixed Payment Arrangements	1,900,000
Tris Karbinal Agreement [Member] | Other Noncurrent Liabilities [Member]
Fixed Payment Arrangements	$ 200,000

Note 9 - Other Liabilities - Sc

Note 9 - Other Liabilities - Schedule of Other Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Fixed payment arrangements	$ 8,337	$ 10,420
Employee retention credit	3,759	0
Operating Lease, Liability	1,289	2,090
Other	106	1,555
Total other liabilities	13,491	14,065
Less: current portion of other liabilities	(8,962)	(7,090)
Total other liabilities, non-current	$ 4,529	$ 6,975

Note 10 - Revolving Credit Fa_2

Note 10 - Revolving Credit Facility (Details Textual) - USD ($) $ in Millions		12 Months Ended
	Jun. 12, 2024	Jun. 30, 2024	Jun. 30, 2023	Mar. 24, 2024
Line of Credit Facility, Remaining Borrowing Capacity		$ 5.6
Eclipse Business Capital LLC Loan Agreement [Member] | Secured Debt [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 14.5
Debt Instrument, Basis Spread on Variable Rate	4.50%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.50%
Debt Instrument, Interest Rate, Effective Percentage		9.90%
Debt Issuance Costs, Current, Net		$ 0.1
Debt Issuance Costs, Net		0.2
Interest Expense, Debt		0.1	$ 0.7
Long-Term Line of Credit		2.4	$ 1.6
Line of Credit Facility, Remaining Borrowing Capacity		$ 5.6
Eclipse Business Capital LLC Loan Agreement [Member] | Secured Debt [Member] | On or Before January 26, 2023 [Member]
Line of Credit Facility, Termination, Fee, Percentage of Commitment				2%
Eclipse Business Capital LLC Loan Agreement [Member] | Secured Debt [Member] | After January 26, 2023 But Before January 26, 2024 [Member]
Line of Credit Facility, Termination, Fee, Percentage of Commitment				1%
Eclipse Business Capital LLC Loan Agreement [Member] | Secured Debt [Member] | After January 26, 2024 But Before January 26, 2025 [Member]
Line of Credit Facility, Termination, Fee, Percentage of Commitment				0.50%

Note 11 - Long-term Debt (Detai

Note 11 - Long-term Debt (Details Textual) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Jun. 12, 2024	Jan. 26, 2022	Jun. 30, 2024	Jun. 30, 2023	Oct. 25, 2022	Mar. 07, 2022
Debt Instrument, Final Payment			$ 0	$ 638
Long-Term Debt, Maturity, Year Four			7,429
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net			$ 266	925
Avenue Capital Issuance [Member]
Shares Issued, Price Per Share (in dollars per share)						$ 25
Avenue Capital Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 24.2			$ 8.6	$ 24.2
Warrants and Rights Outstanding		$ 600
Avenue Capital Loan [Member]
Debt Instrument, Face Amount		$ 15,000
Debt Instrument, Interest Rate, Stated Percentage		3.25%
Loan Processing Fee		$ 400
Debt Instrument, Prepayment Fee, Percentage			16.60%
Interest Expense, Debt			$ 3,400	2,700
Debt Instrument, Final Payment			600
Gain (Loss) on Extinguishment of Debt			$ (594)	$ 0
Avenue Capital Loan [Member] | After January 26, 2024 But Before January 26, 2025 [Member]
Debt Instrument, Prepayment Fee, Percentage			1%
Debt Instrument, Prepayment Fee, Amount			$ 200
Avenue Capital Loan [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		7.40%
Eclipse Term loan [Member]
Debt Instrument, Face Amount	$ 13,000
Interest Expense, Debt			100
Debt Instrument, Term (Year)	4 years
Debt Instrument, Amortization Period (Year)	7 years
Long-Term Debt, Maturity, Year Four			$ 5,600
Debt Instrument, Interest Rate, Effective Percentage			12.40%
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net			$ 300
Eclipse Term loan [Member] | On or Before June 12 2025 [Member]
Debt Instrument, Termination Fee, Percentage	3%
Eclipse Term loan [Member] | After June 12, 2025, but on or before June 12, 2026 [Member]
Debt Instrument, Termination Fee, Percentage	2%
Eclipse Term loan [Member] | After June 12, 2026, but on or before June 12, 2027 [Member]
Debt Instrument, Termination Fee, Percentage	1%
Eclipse Term loan [Member] | After June 12, 2026, but on or before June 12, 2028 [Member]
Debt Instrument, Termination Fee, Percentage	0.50%
Eclipse Term loan [Member] | Secured Overnight Financing Rate (SOFR) [Member]
Debt Instrument, Basis Spread on Variable Rate	7%

Note 11 - Long-term Debt - Sche

Note 11 - Long-term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Term loan principal amount	$ 13,000	$ 15,000
Less: unamortized debt discount and issuance costs	(266)	(925)
Final payment fee	0	638
Financing leases	0	85
Total debt	12,734	14,798
Less: current portion of debt	(1,857)	(85)
Total debt, net of current portion	$ 10,877	$ 14,713

Note 11 - Long-term Debt - Futu

Note 11 - Long-term Debt - Future Principal Payments (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
2025	$ 1,857
2026	1,857
2027	1,857
Long-Term Debt, Maturity, Year Four	7,429
Total future term loan principal payments	13,000
Less: unamortized debt discount and issuance costs	(266)	$ (925)
Less: current portion of debt	(1,857)	(85)
Total debt, net of current portion	$ 10,877	$ 14,713

Note 12 - Fair Value Measurem_3

Note 12 - Fair Value Measurements (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Jun. 14, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 08, 2023	May 31, 2022
Income Statement [Abstract]
Asset Impairment Charges		$ 0	$ 5,705
Fixed Payment Arrangements		8,337	10,420
Impairment of Intangible Assets (Excluding Goodwill)		$ 0	$ 5,600
Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]		Asset Impairment Charges
Tranche B Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		1,806,434		2,173,912
Stock Issued During Period, Shares, Warrants Exercised (in shares)	367,478
Tranche B Pre-Funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,806,434	1,806,434
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.0001
Fair Value, Nonrecurring [Member]
Fixed Payment Arrangements					$ 7,600
Fair Value, Nonrecurring [Member] | Measurement Input, Discount Rate [Member] | Minimum [Member]
Fixed Payment Arrangements, Measurement Input		10%
Fair Value, Nonrecurring [Member] | Measurement Input, Discount Rate [Member] | Maximum [Member]
Fixed Payment Arrangements, Measurement Input		15.40%

Note 12 - Fair Value Measurem_4

Note 12 - Fair Value Measurements - Recurring Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Derivative warrant liabilities	$ 12,745	$ 6,403
Financial liabilities, fair value	12,745	6,403
Fair Value, Inputs, Level 1 [Member]
Derivative warrant liabilities	0	0
Financial liabilities, fair value	0	0
Fair Value, Inputs, Level 2 [Member]
Derivative warrant liabilities	0	0
Financial liabilities, fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Derivative warrant liabilities	12,745	6,403
Financial liabilities, fair value	$ 12,745	$ 6,403

Note 12 - Fair Value Measurem_5

Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024		Jun. 30, 2023
Balance	$ 6,403		$ 1,796
Issued	5,148	[1]	10,998
Settlements	(2,810)	[1]	0
Included in earnings	4,004		(6,391)
Balance	$ 12,745		$ 6,403
[1]Primarily relates to warrants to purchase 2,173,912 common shares issued with the Company’s June 2023 equity financing that were exercised in June 2024. The warrants were converted into 367,478 shares of common stock (“Settlements”) and 1,806,434 pre-funded warrants to purchase shares of common stock with an exercise price of $0.0001 per share (“Issued”). See Note 14 - Stockholders’ Equity and Note 16 - Warrants for further detail.

Note 12 - Fair Value Measurem_6

Note 12 - Fair Value Measurements - Summary of Level 3 Changes (Details) (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Derivative, Gain (Loss) on Derivative, Net	$ (4,004)	$ 4,793
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Derivative, Gain (Loss) on Derivative, Net	Derivative, Gain (Loss) on Derivative, Net

Note 12 - Fair Value Measurem_7

Note 12 - Fair Value Measurements - Valuation Assumptions (Details)	Jun. 30, 2024
Measurement Input, Share Price [Member] | June 2023 Warrants Tranche A [Member]
Derivative liability, measurement input	2.92
Measurement Input, Share Price [Member] | Other Warrants [Member]
Derivative liability, measurement input	2.92	[1]
Measurement Input, Expected Term [Member] | June 2023 Warrants Tranche A [Member]
Derivative liability, measurement input	3.9
Measurement Input, Expected Term [Member] | Other Warrants [Member] | Minimum [Member]
Derivative liability, measurement input	2.6	[1]
Measurement Input, Expected Term [Member] | Other Warrants [Member] | Maximum [Member]
Derivative liability, measurement input	3.2	[1]
Measurement Input, Price Volatility [Member] | June 2023 Warrants Tranche A [Member]
Derivative liability, measurement input	0.803
Measurement Input, Price Volatility [Member] | Other Warrants [Member] | Minimum [Member]
Derivative liability, measurement input	0.832	[1]
Measurement Input, Price Volatility [Member] | Other Warrants [Member] | Maximum [Member]
Derivative liability, measurement input	0.875	[1]
Measurement Input, Risk Free Interest Rate [Member] | June 2023 Warrants Tranche A [Member]
Derivative liability, measurement input	0.044
Measurement Input, Risk Free Interest Rate [Member] | Other Warrants [Member] | Minimum [Member]
Derivative liability, measurement input	0.045	[1]
Measurement Input, Risk Free Interest Rate [Member] | Other Warrants [Member] | Maximum [Member]
Derivative liability, measurement input	0.046	[1]
Measurement Input, Expected Dividend Rate [Member] | June 2023 Warrants Tranche A [Member]
Derivative liability, measurement input	0
Measurement Input, Expected Dividend Rate [Member] | Other Warrants [Member]
Derivative liability, measurement input	0	[1]
[1]Includes August 2022 Warrants, March 2022 Warrants and Avenue Capital Warrants.

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Income Tax Expense (Benefit)	$ 1,768	$ 0
Effective Income Tax Rate Reconciliation, Percent	(12.60%)	0%
Deferred Tax Assets, Gross	$ 138,012	$ 137,332
Deferred Tax Liabilities, Gross	762	1,378
Accrued Income Taxes, Current	300	100
Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Fully Available to Offset Current Fiscal Year Pre-Change Income Subject to Limitation		12,000
Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Disallowed Recognized Built-in Loss, Carried Forward as Operating Loss	8,800	300
Operating Loss Carryforwards	519,600
Operating Loss Carryforwards, Not Subject to Expiration	186,600
Operating Loss Carryforward, Subject To Expire	333,000
Operating Loss Carryforward, Expirations, Ownership Change	329,200
Deferred Tax Assets, Valuation Allowance	137,250	135,954
Unrecognized Tax Benefits	1,313	2,948	$ 2,822
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	3,000
Other Noncurrent Assets [Member]
Deferred Tax Assets, Gross	800	1,400
Other Noncurrent Liabilities [Member]
Deferred Tax Liabilities, Gross	$ 800	$ 1,400

Note 13 - Income Taxes - Provis

Note 13 - Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Federal	$ 1,549	$ 80
State	219	46
Total current tax expense	1,768	126
Federal	0	(109)
State	0	(17)
Total deferred tax expense	0	(126)
Net income tax expense, amount	$ 1,768	$ 0

Note 13 - Income Taxes - Effect

Note 13 - Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Tax at statutory rate, amount	$ (2,956)	$ (3,581)
Tax at statutory rate	21%	21%
State income taxes, net of federal benefit, amount	$ (779)	$ (430)
State income taxes, net of federal benefit	5.50%	2.50%
Stock-based compensation expense, amount	$ 19	$ 0
Stock-based compensation expense	(0.10%)	0%
Contingent consideration, amount	$ 0	$ (193)
Contingent consideration	0%	1.20%
Change in valuation allowance, amount	$ 5,447	$ 4,087
Change in valuation allowance	(38.70%)	(24.00%)
Other, amount	$ 37	$ 117
Other	(0.30%)	(0.70%)
Net income tax expense, amount	$ 1,768	$ 0
Net income tax expense	(12.60%)	0%

Note 13 - Income Taxes - Schedu

Note 13 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Net operating loss carry forward	$ 119,170	$ 113,819
Interest	4,845	4,188
Accrued rebates	3,819	6,994
Warrant derivatives	3,061	1,504
Research and development credits	2,416	2,416
Stock-based compensation expense	1,259	4,250
Accrued expenses	1,027	758
Section 174 capitalization	780	836
Inventory	256	743
Lease liability	305	492
Fixed assets	99	0
Other	975	1,332
Total deferred tax assets	138,012	137,332
Less: valuation allowance	(137,250)	(135,954)
Deferred tax assets, net of valuation allowance	762	1,378
Intangibles	(563)	(845)
ROU asset	(199)	(483)
Fixed assets	0	(50)
Total deferred tax liabilities	(762)	(1,378)
Net deferred tax liabilities	$ 0	$ 0

Note 13 - Income Taxes - Sche_2

Note 13 - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Balance	$ 2,948	$ 2,822
Decrease resulting from current period tax positions	(1,996)	(120)
Increase resulting from current period tax positions	361	246
Balance	$ 1,313	$ 2,948

Note 14 - Stockholders' Equity

Note 14 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Millions						12 Months Ended
		Jun. 14, 2024	Jun. 08, 2023	Aug. 11, 2022	Mar. 07, 2022	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2022	Sep. 28, 2021	Jun. 04, 2021	Jun. 17, 2020
Common Stock, Shares Authorized (in shares)						200,000,000	200,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)						$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized (in shares)						50,000,000	50,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)						$ 0.0001	$ 0.0001
Common Stock, Shares, Issued (in shares)						5,972,638	5,517,174
Preferred Stock, Shares Issued (in shares)						0	0
Common Stock, Shares, Outstanding (in shares)						5,972,638	5,517,174
Proceeds from Warrant Exercises						$ 3.5
Class of Warrant or Right, Issued During Period (in shares)	[1]					1,806,434
Preferred Stock, Shares Outstanding (in shares)						0	0
March 2022 Prefunded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					151,500
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 0.002
March 2022 Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					333,300
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 26
March 2022 Common and Prefunded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)					1.1
Warrants and Rights Outstanding, Term (Year)					5 years
Payment of Financing and Stock Issuance Costs					$ 2.8
August 2022 Prefunded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				87,500
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.02
August 2022 Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				1,265,547
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 8.6			$ 2.32	$ 3.3
Warrants and Rights Outstanding, Term (Year)				5 years
August 2022 Common and Prefunded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1
Warrants and Rights Outstanding, Term (Year)				5 years
Sale of Stock, Price Per Share (in dollars per share)				$ 8.58
Warrants and Rights Outstanding				$ 6
Pre-Funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			430,217
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.0001	$ 0.02
Tranche A Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			2,173,912
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 3.18
Warrants and Rights Outstanding, Term (Year)			5 years
Tranche B Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			2,173,912			1,806,434
Proceeds from Warrant Exercises		$ 3.5
Stock Issued During Period, Shares, Warrants Exercised (in shares)		367,478
Common Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 1.59
Common Warrants Exchanged for PreFunded Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 1.5899
Securities Purchase Agreement Warrants [Member]
Warrants and Rights Outstanding			$ 5
Payments of Stock Issuance Costs			$ 0.6
Tranche B Pre-Funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		1,806,434				1,806,434
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.0001
Warrants and Rights Outstanding		$ 5.1
Class of Warrant or Right, Issued During Period (in shares)		1,806,434
The 2020 Shelf [Member]
Sale of Stock, Maximum Amount of Equity Issuable											$ 100
At-the-market Offering [Member]
Sale of Stock, Maximum Amount of Equity Issuable										$ 30
Stock Issued During Period, Shares, New Issues (in shares)							699,929
Proceeds from Issuance of Common Stock							$ 2.9
The 2021 Shelf [Member]
Sale of Stock, Maximum Amount of Equity Issuable							$ 82.4		$ 100
The 2024 Shelf [Member]
Sale of Stock, Maximum Amount of Equity Issuable						$ 100
The March 2022 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)					151,500
Proceeds from Issuance or Sale of Equity					$ 7.6
Payment of Financing and Stock Issuance Costs					$ 0.8
The August 2022 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)				1,075,290
Proceeds from Issuance or Sale of Equity				$ 10
Payment of Financing and Stock Issuance Costs				$ 0.9
Sale of Stock, Price Per Share (in dollars per share)				$ 8.6
Securities Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			1,743,695
Proceeds from Issuance or Sale of Equity			$ 4
Payment of Financing and Stock Issuance Costs			$ 3.4
Restricted Stock [Member]
Common Stock, Shares, Outstanding (in shares)						25,360
[1]The warrants issued during fiscal 2024 were a result of 1,806,434 Tranche B Warrants being exercise to 1,806,434 Tranche B Pre-Funded Warrants.

Note 15 - Equity Incentive Pl_3

Note 15 - Equity Incentive Plans (Details Textual) - USD ($) $ / shares in Units, $ in Thousands						12 Months Ended
	May 18, 2023	Dec. 19, 2022	Jan. 17, 2022	Apr. 19, 2021	Jun. 01, 2015	Jun. 30, 2024	Jun. 30, 2023	Feb. 13, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)						146,539	52,762
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)						113,500	49,212
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)						$ 1.74	$ 4
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						8 months 12 days
Share-Based Payment Arrangement, Expense						$ 2,913	$ 6,046
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount						0
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount						$ 200	$ 100
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)							1 year 10 months 24 days
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)						24,105	38,075
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)						12,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)						$ 1.77
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)						1,775	4,963
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)						0	0
The 2023 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	200,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	87,129					182,322
The 2023 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	10 years
The 2023 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years
The 2023 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	4 years
The 2023 Equity Incentive Plan [Member] | Restricted Stock and Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years
The 2023 Equity Incentive Plan [Member] | Restricted Stock and Restricted Stock Units (RSUs) [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	4 years
The 2023 Equity Incentive Plan [Member] | Restricted Stock [Member] | Management [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)						12,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)						$ 1.77
The 2023 Equity Incentive Plan [Member] | Restricted Stock [Member] | Management [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage						33.333%
The 2023 Equity Incentive Plan [Member] | Restricted Stock [Member] | Management [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage						8.333%
The 2015 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)								250,000
The 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)					10 years
The 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)					3 years
The 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)					4 years
The 2015 Plan [Member] | Restricted Stock [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						2 years 6 months
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount						$ 1,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value						$ 100
The 2015 Plan [Member] | Restricted Stock [Member] | Management [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)							6,825
The 2015 Plan [Member] | Restricted Stock [Member] | Management [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage							33.333%
The 2015 Plan [Member] | Restricted Stock [Member] | Management [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage							8.333%
The 2015 Plan [Member] | Restricted Stock [Member] | Two Former Board Members [Member]
Share-Based Payment Arrangement, Expense							$ 1,500
The 2015 Plan [Member] | Restricted Stock [Member] | Board Members [Member]
Share-Based Payment Arrangement, Expense		$ 600
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Grants Rescinded		25%
The 2015 Plan [Member] | Restricted Stock [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)					4 years
The 2015 Plan [Member] | Restricted Stock [Member] | Minimum [Member] | Management [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)							$ 3.31
The 2015 Plan [Member] | Restricted Stock [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)					10 years
The 2015 Plan [Member] | Restricted Stock [Member] | Maximum [Member] | Management [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)							$ 13.4
The 2015 Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)					4 years
Neos 2015 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)				5,272
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)				3,486
Neos 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)				10 years
Neos 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)				1 year
Neos 2015 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)				4 years
Neos 2015 Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)				1,786
Non-plan [Member] | Restricted Stock [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						7 months 6 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)					4
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount						$ 200
Non-plan [Member] | Restricted Stock [Member] | Management [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			5,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 27
Non-plan [Member] | Restricted Stock [Member] | Management [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage			33.333%
Non-plan [Member] | Restricted Stock [Member] | Management [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage			8.333%

Note 15 - Equity Incentive Pl_4

Note 15 - Equity Incentive Plans - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Outstanding, options (in shares)	52,762
Outstanding, options, weighted average exercise price (in dollars per share)	$ 18.37
Outstanding, options, weighted average remaining contractual life (Year)	8 years 9 months 18 days	9 years 1 month 6 days
Granted, options (in shares)	113,500	49,212
Granted, options, weighted average exercise price (in dollars per share)	$ 1.74	$ 4
Granted, options, weighted average remaining contractual life (Year)	9 years 2 months 12 days
Forfeited/Cancelled, options (in shares)	(16,610)
Forfeited/Cancelled, options, weighted average exercise price (in dollars per share)	$ 3.2
Expired, options (in shares)	(3,113)
Expired, options, weighted average exercise price (in dollars per share)	$ 66.84
Outstanding, options (in shares)	146,539	52,762
Outstanding, options, weighted average exercise price (in dollars per share)	$ 6.18	$ 18.37
Exercisable, options (in shares)	25,068
Exercisable, options, weighted average exercise price (in dollars per share)	$ 26.06
Exercisable, options, weighted average remaining contractual life (Year)	8 years

Note 15 - Equity Incentive Pl_5

Note 15 - Equity Incentive Plans - Stock Options Outstanding (Details)	12 Months Ended
	Jun. 30, 2024 $ / shares shares
Range of exercise prices (in dollars per share)	$ 6.18
Number of options outstanding (in shares) | shares	146,539
Weighted average remaining contractual life of options outstanding (Year)	8 years 9 months 18 days
Number of options exercisable (in shares) | shares	25,068
Weighted average exercise price (in dollars per share)	$ 225.74
Exercise Price Range One [Member]
Range of exercise prices (in dollars per share)	$ 1.73
Number of options outstanding (in shares) | shares	102,000
Weighted average remaining contractual life of options outstanding (Year)	9 years 1 month 6 days
Exercise Price Range Two [Member]
Range of exercise prices (in dollars per share)	$ 2.53
Number of options outstanding (in shares) | shares	1,500
Weighted average remaining contractual life of options outstanding (Year)	9 years 7 months 6 days
Exercise Price Range Three [Member]
Range of exercise prices (in dollars per share)	$ 16.85
Number of options outstanding (in shares) | shares	43,039
Weighted average remaining contractual life of options outstanding (Year)	8 years 1 month 6 days
Number of options exercisable (in shares) | shares	25,068
Weighted average exercise price (in dollars per share)	$ 225.74
Exercise Price Range Three [Member] | Minimum [Member]
Range of exercise prices (in dollars per share)	4
Exercise Price Range Three [Member] | Maximum [Member]
Range of exercise prices (in dollars per share)	$ 290

Note 15 - Equity Incentive Pl_6

Note 15 - Equity Incentive Plans - Restricted Stock Activity (Details) - Restricted Stock [Member]	12 Months Ended
	Jun. 30, 2024 $ / shares shares
Unvested, shares (in shares) | shares	38,075
Unvested, weighted average grant date fair value (in dollars per share) | $ / shares	$ 142.2
Granted, shares (in shares) | shares	12,500
Granted, weighted average grant date fair value (in dollars per share) | $ / shares	$ 1.77
Vested, shares (in shares) | shares	(25,971)
Vested, weighted average grant date fair value (in dollars per share) | $ / shares	$ 113.37
Forfeited/cancelled, shares (in shares) | shares	(499)
Forfeited/cancelled, weighted average grant date fair value (in dollars per share) | $ / shares	$ 147.15
Unvested, shares (in shares) | shares	24,105
Unvested, weighted average grant date fair value (in dollars per share) | $ / shares	$ 100.34

Note 15 - Equity Incentive Pl_7

Note 15 - Equity Incentive Plans - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Jun. 30, 2024 $ / shares shares
Unvested, shares (in shares) | shares	4,963
Unvested, weighted average grant date fair value (in dollars per share) | $ / shares	$ 25.62
Vested, shares (in shares) | shares	(2,249)
Vested, weighted average grant date fair value (in dollars per share) | $ / shares	$ 24.28
Forfeited/cancelled, shares (in shares) | shares	(939)
Forfeited/cancelled, weighted average grant date fair value (in dollars per share) | $ / shares	$ 31.6
Unvested, shares (in shares) | shares	1,775
Unvested, weighted average grant date fair value (in dollars per share) | $ / shares	$ 24.14

Note 15 - Equity Incentive Pl_8

Note 15 - Equity Incentive Plans - Stock Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Total stock-based compensation expense	$ 2,913	$ 6,046
Cost of Sales [Member]
Total stock-based compensation expense	2	28
Research and Development Expense [Member]
Total stock-based compensation expense	6	30
Selling and Marketing Expense [Member]
Total stock-based compensation expense	0	23
General and Administrative Expense [Member]
Total stock-based compensation expense	$ 2,905	$ 5,965

Note 16 - Warrants (Details Tex

Note 16 - Warrants (Details Textual) $ / shares in Units, $ in Millions

12 Months Ended

Jun. 14, 2024 USD ($) $ / shares shares

Jun. 08, 2023 USD ($) $ / shares shares

Jan. 06, 2023

Mar. 07, 2022 USD ($) $ / shares shares

Jun. 30, 2024 USD ($) shares

Jun. 30, 2023 $ / shares shares

Dec. 31, 2022 $ / shares

Oct. 25, 2022 $ / shares

Aug. 11, 2022 $ / shares shares

Jan. 26, 2022 USD ($) $ / shares

Proceeds from Warrant Exercises | $

$ 3.5

Class of Warrant or Right, Outstanding (in shares)

6,075,880

[1]

6,538,052

[2]

Reverse Stock Split [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

20

Pre-Funded Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

430,217

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 0.0001

$ 0.02

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)

1

Tranche A Common Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

2,173,912

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 3.18

Warrants and Rights Outstanding, Term (Year)

5 years

Tranche B Common Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

2,173,912

1,806,434

Proceeds from Warrant Exercises | $

$ 3.5

Stock Issued During Period, Shares, Warrants Exercised (in shares)

367,478

Common Warrants [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 1.59

Common Warrants Exchanged for PreFunded Warrants [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 1.5899

Tranche B Pre-Funded Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

1,806,434

1,806,434

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 0.0001

Warrants and Rights Outstanding | $

$ 5.1

August 2022 Prefunded Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

87,500

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 0.02

August 2022 Common Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

1,265,547

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 2.32

$ 3.3

$ 8.6

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)

1

Warrants and Rights Outstanding, Term (Year)

5 years

August 2022 Common Warrants [Member] | Minimum [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 2.32

August 2022 Common Warrants [Member] | Maximum [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

2,325,581

March 2022 Prefunded Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

151,500

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 0.002

March 2022 Common Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

333,300

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 26

March 2022 Common and Prefunded Warrants [Member]

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)

1.1

Warrants and Rights Outstanding, Term (Year)

5 years

Payment of Financing and Stock Issuance Costs | $

$ 2.8

Avenue Capital Warrants [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 24.2

$ 8.6

$ 24.2

Warrants and Rights Outstanding | $

$ 0.6

Liability Warrants [Member]

Class of Warrant or Right, Outstanding (in shares)

3,821,115

6,068,763

Liability Pre-Funded Warrants [Member]

Class of Warrant or Right, Outstanding (in shares)

430,217

430,217

Equity Warrants [Member]

Class of Warrant or Right, Outstanding (in shares)

18,114

39,072

Liability Tranche B Prefunded Warrants [Member]

Class of Warrant or Right, Outstanding (in shares)

1,806,434

Securities Purchase Agreement [Member]

Stock Issued During Period, Shares, New Issues (in shares)

1,743,695

Proceeds from Issuance or Sale of Equity | $

$ 4

Payment of Financing and Stock Issuance Costs | $

3.4

Securities Purchase Agreement Warrants [Member]

Warrants and Rights Outstanding | $

5

Payments of Stock Issuance Costs | $

$ 0.6

The March 2022 Offering [Member]

Stock Issued During Period, Shares, New Issues (in shares)

151,500

Proceeds from Issuance or Sale of Equity | $

$ 7.6

Payment of Financing and Stock Issuance Costs | $

$ 0.8

[1]The number of warrants outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,806,434 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants.[2]The number of warrants outstanding as of June 30, 2023, is comprised of 6,068,763 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants and 39,072 equity classified warrants.

Note 16 - Warrants - Schedule o

Note 16 - Warrants - Schedule of Warrants Outstanding (Details) - $ / shares		12 Months Ended
		Jun. 30, 2024		Jun. 30, 2023	[1]
Outstanding, balance (in shares)	[1]	6,538,052
Outstanding, weighted average remaining contractual term (Year)	[2]	3 years 1 month 6 days	[3]	4 years 8 months 12 days
Warrants issued (2) (in shares)	[4]	1,806,434
Warrants exercised (in shares)		(2,247,648)
Warrants expired (in shares)		(20,958)
Outstanding, balance (in shares)		6,075,880	[3]	6,538,052
Weighted Average [Member]
Outstanding, weighted average exercise price (in dollars per share)	[1]	$ 4.42
Warrants issued, weighted average exercise price (in dollars per share)	[4]	0.0001
Warrants exercised, weighted average exercise price (in dollars per share)		1.61
Warrants expired, weighted average exercise price (in dollars per share)		300
Outstanding, weighted average exercise price (in dollars per share)		$ 3.71	[3]	$ 4.42
[1]The number of warrants outstanding as of June 30, 2023, is comprised of 6,068,763 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants and 39,072 equity classified warrants.[2]As pre-funded warrants do not have an expiration date, they have been excluded from the calculation of the weighted average remaining contractual life in years.[3]The number of warrants outstanding as of June 30, 2024, is comprised of 3,821,115 liability classified warrants, 430,217 liability classified June 2023 Pre-Funded Warrants, 1,806,434 liability classified Tranche B Pre-Funded Warrants and 18,114 equity classified warrants.[4]The warrants issued during fiscal 2024 were a result of 1,806,434 Tranche B Warrants being exercise to 1,806,434 Tranche B Pre-Funded Warrants.

Note 17 - Restructuring Costs_2

Note 17 - Restructuring Costs (Details Textual) - Grand Prairie, Texas Manufacturing Site [Member] $ in Millions	12 Months Ended
	Jun. 30, 2024 USD ($)
Severance Costs	$ 0.9
Business Exit Costs	$ 0.4

Note 17 - Restructuring Costs -

Note 17 - Restructuring Costs - Summary of Restructuring Costs (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2024 USD ($)
Restructuring costs	$ 3,095
Employee Severance [Member]
Restructuring costs	1,145	[1]
Exit and Disposal Activities [Member]
Restructuring costs	1,220	[1]
Inventory Write Downs [Member]
Restructuring costs	730	[2]
Consumer Health Segment [Member] | Consumer Health Segment [Member]
Restructuring costs	939	[3]
Consumer Health Segment [Member] | Employee Severance [Member]
Restructuring costs	20	[1],[3]
Consumer Health Segment [Member] | Exit and Disposal Activities [Member]
Restructuring costs	189	[1],[3]
Consumer Health Segment [Member] | Inventory Write Downs [Member]
Restructuring costs	730	[2],[3]
Grand Prairie, Texas Manufacturing Site [Member]
Restructuring costs	2,156	[4]
Grand Prairie, Texas Manufacturing Site [Member] | Employee Severance [Member]
Restructuring costs	1,125	[1],[4]
Grand Prairie, Texas Manufacturing Site [Member] | Exit and Disposal Activities [Member]
Restructuring costs	1,031	[1],[4]
Grand Prairie, Texas Manufacturing Site [Member] | Inventory Write Downs [Member]
Restructuring costs	$ 0	[2],[4]
[1]Expense associated with severance and employee benefits and exit and disposal activities are included in restructuring costs in the consolidated statements of operations.[2]Expense associated with inventory write-downs is recorded in cost of sales in the consolidated statements of operations.[3]Expense associated with the wind down of the Consumer Health Segment is related to the Consumer Health Segment.[4]Expense associated with the closure of the Grand Prairie, Texas manufacturing site is related to the Rx Segment.

Note 18 - Commitments and Con_2

Note 18 - Commitments and Contingencies (Details Textual)		12 Months Ended
	Jun. 21, 2021 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	May 31, 2023 USD ($)	Feb. 22, 2023 shares	May 29, 2020 USD ($)	Jan. 31, 2020 USD ($)	Nov. 01, 2019 USD ($)	Feb. 28, 2015
Fixed Payment Arrangements		$ 8,337,000	$ 10,420,000
Sabby Volatility Warrant Master Fund Ltd. [Member] | Sabby Litigation [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares					312,908
Sabby Volatility Warrant Master Fund Ltd. [Member] | Sabby Litigation [Member] | Sabby Litigation Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares					575,000
Walleye Opportunities Master Fund Ltd. [Member] | Sabby Litigation [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares					54,146
Walleye Opportunities Master Fund Ltd. [Member] | Sabby Litigation [Member] | Sabby Litigation Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares					100,000
Office Space in Berwyn, Pennsylvania [Member]
Lessee, Operating Lease, Renewal Term (Year)		5 years
Operating Lease, Undiscounted Minimum Monthly Payment		$ 13,000
Principal Office Denver Colorado [Member]
Lessee, Operating Lease, Renewal Term (Year)				5 years
Operating Lease, Undiscounted Minimum Monthly Payment				$ 15,500
Lessee, Operating Lease, Term of Contract (Year)				5 years 6 months					5 years
Tris Karbinal Agreement [Member]
Supply and Distribution Commitment, Period (Year)		20 years
Supply and Distribution Commitment, Royalty, Percentage of Net Sales		23.50%
Supply and Distribution Agreement, Minimum Sales Per Year		70,000
Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit		$ 30
Supply and Distribution Agreement, Maximum Milestone Obligations		3,000,000
Supply and Distribution Agreement, First Milestone, Minimum Net Revenues		40,000,000
Tris Karbinal Agreement [Member] | Other Current Liabilities [Member]
Fixed Payment Arrangements		1,900,000
Tris Karbinal Agreement [Member] | Other Noncurrent Liabilities [Member]
Fixed Payment Arrangements		200,000
Tris Karbinal Agreement [Member] | Maximum [Member]
Supply and Distribution Agreement, Royalty Make Whole Payment Under Annual Minimum Sales Commitment, Per Unit		2,100
Fixed Payment Arrangement Assumed from Cerecor Inc. [Member]
Fixed Payment Arrangements, Periodic Payment Obligations, Number								2
Fixed Payment Arrangements, Monthly Payment Amount								$ 100,000
Fixed Payment Arrangements, Balloon Payment Amount						$ 15,000,000		$ 15,000,000
Fixed Payment Arrangements, Payment Amount, Paid	$ 2,800,000
Fixed Payment Arrangements	3,000,000
Fixed Payment Arrangement, Quarterly Payments	$ 500,000
Fixed Payment Arrangement Assumed from Cerecor Inc. [Member] | The Pediatric Portfolio [Member]
Fixed Payment Arrangements, Balloon Payment Amount		$ 100,000					$ 200,000

Note 19 - License Agreements (D

Note 19 - License Agreements (Details Textual) - USD ($) $ in Millions	1 Months Ended
	Apr. 30, 2020	Feb. 29, 2016
Healight [Member]
License Agreement, Initial License Fee Paid	$ 0.3
License Agreement, Patent Prosecution Fees Paid	$ 0.1
The 2014 License Agreement, Shire [Member]
License Agreement, Up-front, Non-refundable License Fee Paid, Maximum		$ 1

Note 20 - Segment Information_2

Note 20 - Segment Information (Details Textual)	10 Months Ended	12 Months Ended
	Apr. 29, 2024	Jun. 30, 2024
Number of Reportable Segments	2	2

Note 20 - Segment Information -

Note 20 - Segment Information - Schedule of Segment Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Net revenue	$ 81,002	$ 107,399
Income (loss) from operations	(5,254)	(17,065)
Depreciation and amortization	7,456	7,387
Stock-based compensation expense	2,913	6,046
Restructuring costs	2,365	0
Impairment and write-off expense		5,705
Rx Segment [Member]
Net revenue	65,183	73,799
Income (loss) from operations	(1,590)	(7,358)
Depreciation and amortization	5,909	6,271
Stock-based compensation expense	2,373	5,722
Restructuring costs	2,156
Impairment and write-off expense		2,730
Consumer Health [Member]
Net revenue	15,819	33,600
Income (loss) from operations	(3,664)	(9,707)
Depreciation and amortization	1,547	1,116
Stock-based compensation expense	540	324
Restructuring costs	$ 209
Impairment and write-off expense		$ 2,975

Note 21 - Subsequent Events (De

Note 21 - Subsequent Events (Details Textual) $ in Millions	1 Months Ended
	Jul. 31, 2024 USD ($)
Subsequent Event [Member]
Revenue-based Royalty Costs	$ 0.5